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are provided based on the main levels of evidence (1–3). 
Toolboxes for everyday clinical practice are provided.
Conclusions The first up-to-date Italian guidelines for the 
primary, secondary, and tertiary prevention of osteoporosis 
and osteoporotic fractures are presented.
Keywords Fracture · Fracture liaison service · Guidance · 
Bisphosphonates · Denosumab · Teriparatide · Strontium 
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Scope of the guidelines
These recommendations were conceived by the Italian Soci-
ety for Orthopaedics and Traumatology (Società Italiana di 
Ortopedia e Traumatologia, SIOT), which was founded in 
Rome (Italy) in 1892 to promote continuous education in the 
field of modern orthopedics [1]. These guidelines—which 
are primarily intended for orthopedic surgeons, bone spe-
cialists, and general practitioners, but should prove useful 
to health-care professionals in general—were written to 
promote improved diagnosis, prevention, and treatment of 
osteoporosis and its consequences.
Guidelines for primary, secondary, or tertiary prevention 
will be described, mainly focusing on postmenopausal osteo-
porosis and osteoporosis in men. Although these guidelines 
are not intended to cover all situations, especially in the field 
of secondary osteoporosis, some special but not infrequent 
conditions that are characterized by altered bone strength 
and lead to some management issues (such as patients 
with juvenile osteoporosis and chronic kidney disease) are 
addressed. The identification of subjects at high risk for frac-
tures are highlighted, and specific thresholds for intervention 
are defined. The management and prevention of common or 
rare side effects due to antiosteoporotic treatments employed 
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in clinical practice will be addressed. Special emphasis will 
be given to the establishment of secondary prevention strate-
gies (i.e., fracture liaison services) that are usually activated 
by secondary or tertiary referral centers and provide a link 
between the initial orthopedic treatment of major osteoporo-
tic fractures (such as hip or vertebral fractures) and the ini-
tiation of therapy to prevent further fractures.
These guidelines were drafted by a scientific committee 
within the SIOT according to the principles of evidence-
based medicine. Thus, it mainly focuses on grade A recom-
mendations (“good evidence to recommend the action”), 
as based on consistent level 1 studies, and grade B recom-
mendations, as based on consistent level 2 or 3 studies or 
extrapolations from level 1 studies. Thus, data obtained from 
large randomized controlled trials (RCTs), meta-analyses, 
and large systematic reviews of the best available evidence 
(i.e., level 1) were primarily exploited to prepare these 
guidelines. Cost-effectiveness was also taken into account 
where possible. When there was minimal evidence on a spe-
cific subject, recommendations were made based on expert 
opinion regarding good practice as well as the current Italian 
reimbursement policy. Moreover, existing knowledge was 
incorporated by taking into account the recently published 
European guidance for the diagnosis and management of 
osteoporosis in postmenopausal women, along with addi-
tional position papers drafted by other European societies/
national institutes, and subsequent updates reported by the 
International Osteoporosis Foundation website [2, 3]. At 
the end of each of the following sections, a tool box with 
grade A, B, and C recommendations—which are based on 
the main lines of evidence described—is provided as guid-
ance for clinical practice.
Definition of osteoporosis and epidemiology
Osteoporosis is a systemic skeletal disease characterized by 
decreased bone density and a deterioration in bone quality 
(microarchitectural changes), leading to compromised bone 
strength and an enhanced risk of fractures that are not due 
to significant trauma [4].
The operational definition of osteoporosis proposed 
by the World Health Organization (WHO) is a bone min-
eral density (BMD), as measured using dual-energy X-ray 
absorptiometry (DEXA), that is 2.5 standard deviations (SD) 
or more below the average value for young healthy women 
(i.e., T-score < − 2.5 SD) in post-menopausal women and 
men aged ≥ 50 years [5] (Table 1). This definition origi-
nally relied on DEXA measurements at the hip. It was sub-
sequently extended to include lumbar spine DEXA measure-
ments. Established or severe osteoporosis is defined as when 
a BMD T-score ≤ − 2.5 SD is associated with a history 
of fragility fracture. However, it should be noted that the 
abovementioned criteria provide a densitometric definition 
of osteoporosis that can only be employed in clinical prac-
tice after a comprehensive assessment of the differential 
diagnosis.
Osteoporosis is one of the major noncommunicable dis-
eases, accounting for 1.75% of the global burden in Europe 
[6]. The prevalence of osteoporosis and its consequences 
(i.e., fragility fractures) is increasing worldwide in parallel 
with global population aging.
Osteoporotic fractures occur when a mechanical stress 
applied to the bone exceeds its strength. The most frequent 
fracture sites are the vertebral body, the proximal femur, 
the proximal humerus, and the distal radius. According to 
the WHO, fragility fractures result from low-energy trauma 
due to mechanical forces equivalent to a fall from a stand-
ing height or less, which would not ordinarily cause a frac-
ture [7]. It is now believed that skeletal fragility requires 
both decreased bone density and poor bone quality, defined 
as alterations in bone architecture, bone geometry, and 
the material properties of the microstructural constituents 
such as collagen and mineral, as well as the presence of 
microdamage.
The probability of low-trauma fracture increases with age 
in both sexes. At 45 years old, the risk of such a fracture is 
47.3% for women and 23.8% in men in Western Europe [8]. 
In women, this risk exceeds the risk for beast cancer and is 
similar to the risk for coronary heart disease.
The estimate for the year 2000 was 9.0 million osteo-
porotic fractures worldwide (1.7 million forearm fractures, 
1.4 million clinical vertebral fractures, 1.6 million hip frac-
tures), with nearly 35% occurring in Europe [6]. Figures 
are expected to increase over the next few decades globally, 
with the number of fractures expected to double by 2040 [9].
Osteoporotic fractures lead to increased morbidity and 
mortality, as demonstrated by the data on disability-adjusted 
life years (DALYs; i.e., the number of years lost due to ill 
health, disability, or early death), which are employed to 
estimate overall disease burden [10]. Indeed, in Europe, the 
estimated number of DALYs lost because of osteoporosis is 
2.0 million [10].
In Italy, it has been estimated that about 18.5 and 10% 
of women and men, respectively, suffer from osteoporosis, 
and it is expected that the number of osteoporotic patients 
will increase by 25% in the next 20 years [11]. According to 
Table 1  World Health Organization cutoffs used in the diagnosis of 
osteoporosis (BMD at the hip)
Normal bone T-score > − 1 SD
Osteopenia T-score between − 1 and − 2.5 SD
Osteoporosis T-score < − 2.5 SD
Established (severe) osteo-
porosis
T-score < − 2.5 SD + fragility fracture
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data from the Italian Ministry of Health, there is an annual 
incidence of 410,000 fragility fractures [12]. Hip fractures 
are undoubtedly the most direct consequences. In Italy, more 
than 500,000 hip fractures occurred in the elderly popula-
tion and there was a 28.5% increase in hospitalizations over 
a period of 6 years [13]. In hip fracture patients, the 30-day 
and 1-year mortality rates are 9 and 36%, respectively [14, 
15]. The socioeconomic burden of hip fragility fractures in 
elderly individuals has increased such that it has become 
comparable to that of acute myocardial infarction and stroke 
[16].
The main types of osteoporosis
Primary or idiopathic osteoporosis, which includes juve-
nile, postmenopausal, and senile osteoporosis, is the most 
common type of osteoporosis. Secondary osteoporosis may 
ensue from several diseases, such as endocrine (hypog-
onadism, hypocortisolism, hyperparathyroidism, acromeg-
aly, diabetes mellitus), hematological (thalassemia, multiple 
myeloma), gastrointestinal (malabsorption, celiac disease), 
rheumatic (rheumatoid arthritis, systemic lupus erythemato-
sus, ankylosing spondylitis, scleroderma), and kidney (renal 
failure, chronic tubular acidosis) disorders, or from medica-
tions such as glucocorticoids, anticoagulants, diuretics, and 
others [11, 17] (Table 2). The characteristics of the main 
forms of osteoporosis will now be briefly described.
Juvenile osteoporosis
The term juvenile osteoporosis, or idiopathic juvenile osteo-
porosis (IJO), is used to indicate osteoporosis in children and 
adolescents, and usually does not refer to any specific type 
of osteoporosis in these age groups.
Bone loss may occur from infancy to adolescence because 
of genetic mutations resulting in a reduced amount and 
impaired quality of the fibrous component of bone (e.g., 
leading to osteogenesis imperfecta), or may be secondary to 
a spectrum of other conditions, such as prolonged immobi-
lization and chronic inflammatory diseases. Moreover, the 
use of anticonvulsants or steroids or the presence of life-
threatening conditions such as leukemia may lead to fra-
gility fractures, particularly at the spine. If an underlying 
cause cannot be identified, it is defined as IJO. This condi-
tion includes a group of heritable disorders characterized 
by low bone density and skeletal fragility, but without the 
extraskeletal findings reported in osteogenesis imperfecta. 
Skeletal involvement in patients with IJO is the result of 
impaired osteoblast activity and mainly affects cancellous 
bone [18]. Impaired activation of Wnt–β-catenin signaling 
was demonstrated in autosomal dominant IJO with heterozy-
gous mutations in WNT1 [19, 20]. Recently, a new gene 
mutation in PLS3, which encodes plastin-3, was found in 
X-linked IJO, but the pathogenic role of this protein in bone 
diseases must be clarified [21].
The Official Pediatric Positions of the International Soci-
ety for Clinical Densitometry (ISCD) defined osteoporosis 
in children on the basis of a history of one or multiple ver-
tebral fragility fractures or the presence of both a clinically 
significant fracture history—defined as the occurrence of at 
least two long bone fractures by 10 years of age or three or 
more fractures of long bones up to the age of 19 years—in 
the absence of local disease or high-energy trauma, as well 
as a BMD Z-score ≤ − 2.0 SD at the lumbar spine and/or 
the total body less head (TBLH) adjusted for age, gender, 
and body size [22] (grade B recommendation). The total hip 
and the femoral neck are not preferred measurement sites 
for growing children because of the inherent variability in 
skeletal development.
In infants and children, a diagnosis of low bone mass or 
BMD should be reported when the BMD Z-score is less 
than − 2.0 SD and there is no fracture history. However, 
in children aged less than 5 years, interpreting the DEXA 
results may not be appropriate because the impact of growth 
delay is not quantifiable.
Postmenopausal osteoporosis
Postmenopausal osteoporosis is a type of primary osteo-
porosis where the pathogenesis is associated with estrogen 
depletion, which enhances the bone loss that occurs with 
aging. This condition is characterized by a specific skeletal 
disease pattern, including prevalent trabecular bone loss and 
perforation compared to cortical bone loss, leading to site-
specific fracture risks at vertebral bodies and at the distal 
radius [23, 24].
The rate of bone loss after menopause is a major factor 
in the development of postmenopausal osteoporosis. This is 
often characterized by high bone turnover, which is associ-
ated with a higher risk of trabecular perforation or intra-
cortical porosity [23]. It is difficult to predict the clinical 
outcome for each individual due to the variability in the rate 
of loss after menopause [25]. In the postmenopausal period, 
estrogen deficiency leads to bone loss through both bone 
marrow expansion and endosteal resorption, whereas peri-
osteal apposition occurs—mainly in response to mechani-
cal stress—to counteract reduced bone strength [26, 27]. A 
low serum concentration of estrogen after menopause may 
lead to inhibited periosteal bone formation, as suggested 
by the results of a previous experimental study [28]. In the 
absence of this compensatory mechanism, the section modu-
lus, which reflects the ability of bone to withstand bending 
forces, decreases because of bone marrow expansion. Both 
bone quality and BMD are independent predictive factors 
for fragility fractures [29, 30]. However, the BMD is the 
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best predictive factor for fracture in postmenopausal women, 
despite the fact that bone geometry and microarchitecture 
are also site-specific risk factors for osteoporotic fracture 
(grade A recommendation).
Osteoporosis in men
Osteoporosis is a major public health problem, even in males. 
Nevertheless, male osteoporosis is still underestimated and 
undertreated, which has significant clinical and social conse-
quences considering that the aging male population is grow-
ing exponentially [31]. About 20% of all hip fractures occur 
in men, and the incidence of vertebral fractures is about half 
that for women [32]. However, mortality and morbidity for 
major osteoporotic fractures in men are higher than those 
for women [33].
Primary osteoporosis in men accounts for about 40% 
of all cases [34]. Secondary osteoporosis ensues from 
Table 2  Secondary causes of osteoporosis. Reproduced (with permission) from Table 7 of the Guidance for the diagnosis, prevention and ther‑
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several conditions (i.e., hypogonadism, alcoholism, multi-
ple myeloma, hyperparathyroidism, malabsorption, and use 
of corticosteroids), and is the most common type of male 
osteoporosis [35]. Special consideration should be given to 
osteoporosis associated with androgen deprivation therapy 
for prostate cancer, a common disease in men, because such 
treatment is accompanied by significant bone loss and an 
increased risk of fragility fractures [36]. Therefore, the 
exclusion of underlying pathological conditions in male 
osteoporosis is mandatory (grade B recommendation).
The management strategies for this condition are based on 
data derived from clinical trials performed on osteoporotic 
women [37]. This approach is simplistic, however, because 
the pathogenic mechanisms are substantially different in 
men and women, even though the definition of osteoporosis 
is the same for both genders.
It should be noted that only 21% of all nonvertebral 
fractures and 39% of all hip fractures occur in men with a 
T-score < − 2.5 SD. This contrasts with data obtained for 
the female population, in which about 64% of all hip fragility 
fractures occur in the osteoporotic range [38].
According to the ISCD Positions [39], bone densitometry 
is required to confirm a diagnosis of osteoporosis in men 
over 70 years or those with a history of fragility fractures 
(grade C recommendation). Moreover, BMD measurement 
using DEXA is justified for male subjects at any age in the 
presence of a risk factor for low bone mass, such as low body 
weight, high-risk medication use, or a disease or condition 
associated with bone loss. The WHO criteria for diagnos-
ing male osteoporosis in individuals aged 50 years or more 
are currently the same as those used for women (grade A 
recommendation).
A recent study has also shown that biochemical tests 
prescribed to assess and achieve a differential diagnosis of 
metabolic bone diseases are not useful for identifying sec-
ondary causes of osteoporosis in older men [40]. On the 
other hand, Harvey et al. [41] demonstrated that algorithms 
of fracture risk, such as FRAX, are able to predict incident 
falls in elderly men.
In men, as well as in women, the most viable approach for 
the diagnosis of osteoporosis includes clinical assessment, 
the use of algorithms of fracture risk, and DEXA scans (see 
the section “Diagnosis of osteoporosis”).
Secondary osteoporosis
Secondary osteoporosis is an umbrella term for all clinical 
conditions where bone involvement is not the main patho-
logical finding; rather, they are characterized (at least in 
part) by adverse consequences of the primary disease itself 
or resulting from related treatments, particularly glucocor-
ticoid (GC) use.
Bone remodeling and bone density are negatively affected 
by several diseases and treatments that are often associated 
with an increased risk of fall. Pathogenetic mechanisms of 
secondary osteoporosis are independent of estrogen defi-
ciency. In fact, about two-thirds of men, > 50% of premeno-
pausal women, but also 20% of postmenopausal women have 
secondary osteoporosis [42].
Secondary osteoporosis is caused by readily identifiable 
conditions such as malignancy, endocrinopathies, systemic 
inflammatory diseases, the use of certain medications (e.g., 
GCs, aromatase inhibitors), as well as by other diseases that 
are more difficult to diagnose, such as hypovitaminosis D, 
hyperparathyroidism, or idiopathic hypercalciuria. Young 
individuals, premenopausal women, men under 65 years of 
age, all patients with accelerated bone loss, patients with 
severe osteoporosis, and patients receiving antiosteoporotic 
treatment who experience bone loss should be investigated 
for other underlying causes of osteoporosis (grade B recom-
mendation). Biochemical evaluation has a sensitivity of 92% 
for the diagnosis of secondary causes of osteoporosis [43]. 
Therefore, laboratory assessment should be prescribed to 
investigate the main cause of bone loss, such as hyperthy-
roidism, hypercortisolism, multiple myeloma, or celiac dis-
ease. It is advisable to perform a double tetracycline labeling 
transiliac bone biopsy to evaluate bone marrow disorders 
(e.g., nonsecretory multiple myeloma or mastocytosis) or 
defective mineralization in patients with fragility fractures 
and normal bone density, which are highly suggestive of 
secondary osteoporosis (grade B recommendation).
In systemic inflammatory disorders such as rheumatoid 
arthritis and inflammatory bowel diseases, chronic therapy 
with the GCs used to control the disease decreases osteoblast 
proliferation and activity and reduces osteoprotegerin (OPG) 
expression, which is already impaired because of the under-
lying disease [44]. Therefore, GC therapy for inflammatory 
conditions increases the bone loss, enhancing its detrimen-
tal effects on bone health. Chronic obstructive pulmonary 
disease (COPD) is characterized by increased production 
of proinflammatory cytokines, particularly TNF-α, which is 
associated with disease severity and loss of bone mass [45]. 
In this condition, patients treated with systemic GCs show 
a high prevalence of vertebral fracture [46]. However, this 
finding has not been confirmed for inhaled GCs, as demon-
strated by the results of a large case–control study suggest-
ing that the fracture risk is increased because of the disease 
severity in COPD rather than because of the inhaled GCs 
[47].
Growing evidence has demonstrated that the pathogenesis 
of bone fragility in diabetes mellitus of both types (1 and 
type 2) is multifactorial [48]. In diabetic patients, osteopo-
rosis is characterized by low bone turnover due to decreased 
bone formation [49].
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Figure 1 summarizes the recommendations for the defini-
tion of osteoporosis in a toolbox.
Diagnosis of osteoporosis
The diagnosis of osteoporosis is based on patient medical 
history, careful physical examination, conventional X-rays of 
the thoracic and lumbar spine, bone mineral density (BMD) 
measurements, and laboratory investigations.
Knowledge of the medical history is essential to achieve 
an accurate diagnosis as well as to estimate the fracture risk. 
The anamnestic investigation should aim to determine the 
presence of any risk factor: a family history of osteoporo-
sis and/or fragility fractures, previous fractures, nutritional 
habits and lifestyle, the use of medications that affect bone 
metabolism, the level of physical activity, and—only in 
women—the duration of ovarian estrogen production (grade 
A recommendation).
Physical examination includes assessment of patient 
posture, which looks for increased kyphosis of the thoracic 
spine, a protruded abdomen, and a loss of body height, 
which may be ascribed to the presence of one or more ver-
tebral deformities (grade A recommendation).
Conventional X-ray of the thoracic and lumbar spine 
is useful for detecting prevalent vertebral fractures. BMD 
measurements are important as they can be used to better 
estimate the individual fracture risk, differentiate between 
mild and severe forms of bone loss, and select the appropri-
ate treatment follow-up (grade A recommendation).
Laboratory tests are mandatory to exclude the main 
forms of secondary osteoporosis and for mineral metabo-
lism assessment (grade A recommendation). Biochemical 
markers of bone turnover and vitamin D status may provide 
additional information on individual fracture risk (grade 
B recommendation). In the absence of major trauma, any 
fracture in adults may suggest a diagnosis of osteoporosis, 
so proper clinical and imaging assessment should be under-
taken (grade A recommendation).
Instrumental evaluation
The instrumental diagnosis of osteoporosis routinely 
includes conventional X-ray of the thoracic and lumbar 
spine for the detection of osteoporotic vertebral fractures, 
dual-energy X-ray absorptiometry (DEXA), and quantita-
tive computed tomography (QCT) [50]. Bone quantitative 
ultrasonography (QUS) measures other parameters of the 
bone (i.e., elasticity and stiffness) that appear to be related 
to mechanical strength [51].
Conventional radiology
Identifying prevalent vertebral fractures requires a dorsal 
and lumbar spine assessment with X-ray or DEXA (grade 
A recommendation). It is important to emphasize that these 
Fig. 1  Toolbox for guidance: definition of osteoporosis
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fractures are often asymptomatic when they first occur and 
may remain undiagnosed for many years or be revealed by an 
X-ray examination performed for other reasons. Indeed, the 
presence of one or more prevalent vertebral fractures and/or 
other previous fragility fractures increases the relative risk 
of additional fragility fractures in the following year. As 
the number and severity of pre-existing/prevalent fractures 
increase, so does the relative risk for further fragility frac-
tures [52]. It is important to exclude vertebral deformities 
due to congenital or acquired causes that may simulate a 
fragility fracture.
A morphometric analysis is required in order to quantify 
abnormal variations in vertebral shape. A semiquantitative 
method (SQ) that measures the anterior, middle, or poste-
rior heights of the dorsal and lumbar vertebral bodies in 
lateral projection via conventional radiography (MRX) or 
with DEXA (vertebral fracture assessment, VFA) is usually 
employed. If one of these three heights decreases by more 
than 20%, the fracture is morphometrically documented 
[53].
Vertebral morphometry is recommended whenever there 
are the following red flags (grade A recommendation):
1. Acute back pain that worsens while standing and/or does 
not improve for several days in a person at high risk for 
a fragility fracture.
2. Unexplained chronic back pain in a patient with a his-
tory of a prevalent fragility fracture.
3. A height reduction of more than 4 cm compared to the 
maximum height reached by the subject or > 2 cm from 
the last control [54, 55].
Dual‑energy X‑ray absorptiometry
The gold standard for quantitative assessment of bone min-
eral status in adults is DEXA, performed at the lumbar spine 
(L1–L4) and hip (total hip or femoral neck) (grade A rec-
ommendation). It accurately and precisely measures bone 
density, which is the best predictor of the risk of osteoporo-
tic fracture. A DEXA examination can also be done at the 
forearm (distal third of the radius), meaning that it mostly 
represents cortical bone, or for the total body less head 
(TBLH; the preferred skeletal site, along with the lumbar 
spine, for measuring BMD in pediatric subjects) [39]. Total 
body DEXA is not recommended for BMD assessment. 
The parameters obtained are bone mineral content (BMC) 
in grams, area in  cm2, and BMD in g/cm2. The presence of 
osteophytes, vascular calcifications, and calculi could lead 
to an overestimation of bone mass.
BMD measurements at the lumbar spine, femoral 
neck, total hip, and distal third of the radius have been 
demonstrated to predict fragility fractures. A meta-analysis 
of 11 prospective cohort studies showed that a reduction in 
BMD of 1SD at all sites can predict fractures with a RR of 
1.5 (95% CI 1.4–1.6). In the same study, lumbar spine and 
hip BMD measurements were able to predict site-specific 
fracture with RRs of 2.3 and 2.6 for vertebral and proximal 
femur fractures, respectively [56].
As previously pointed out, the World Health Organization 
has defined osteoporosis as a BMD of 2.5 standard devia-
tions (SD) below the mean peak bone mass of young healthy 
adults (Table 1) (grade A recommendation). The T-score 
shows the bone density compared with that of a young adult 
(at the age of 35 years) of the same gender. The Z-score is 
calculated in the same way, but the comparison is made with 
someone of the same age, gender, race, height, and weight.
Fractured vertebrae or those with focal thickenings should 
be excluded from the analysis because these alterations 
could reduce the accuracy of the densitometric results. To 
obtain a comprehensive report on the spine, it is necessary 
to analyze at least two lumbar vertebrae. Lumbar densi-
tometry assessment is often inaccurate after 65 years due 
to the aforementioned reasons, and femoral densitometric 
evaluation is therefore preferable after this age (grade A 
recommendation). At the femur, both the neck and the total 
femoral BMD are assessed. The lowest T-score value among 
those obtained at the lumbar spine, femoral neck, and total 
femur is considered for the diagnosis. Measurements at the 
distal forearm are only done when lumbar and/or femoral 
assessment is impractical or inaccurate, in severely obese 
patients, and in patients with hyperparathyroidism.
Bone densitometry is recommended for all women over 
65 years and all males over 70 years of age (grade A recom-
mendation). A prior fragility fracture, increased bone radio-
lucency at conventional X-ray, or clinical risk factors for 
osteoporosis (medications or diseases associated with bone 
loss) require a bone densitometric assessment, independent 
of age (grade A recommendation). In Italy, access to DEXA 
is regulated by regional exemption policies.
The interval between two densitometric assessments 
depends on patient characteristics. Usually a new DEXA 
is not performed until at least 18–24 months have elapsed 
since the previous DEXA, as this allows the least signifi-
cant changes to be detected [39] (grade A recommendation). 
The percentage change in BMD and the T-score are taken 
into account during follow-up. When there is limited access 
to DEXA, vertebral DEXA assessment is preferable to hip 
DEXA assessment to monitor the disease and/or treatment, 
since it better detects the least significant changes and is thus 
able to guide further therapeutic choices.
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Quantitative computed tomography (QCT) and bone 
microarchitecture analysis (BMA)
Quantitative computed tomography (QCT) measures not 
only the BMD and BMC but also the true bone density 
expressed in g/cm3. Its main advantage is its lack of inter-
ference with osteoarthritic processes. Its main limitations are 
the substantially higher radiation dose delivered, its reduced 
accuracy, and that it is relatively expensive [39]. Peripheral 
QCT (p-QCT), which focuses on the peripheral segments 
(i.e., the forearm and tibia), allows a three-dimensional 
reconstruction of the trabecular bone to be obtained, provid-
ing information on bone microarchitecture. High spatial res-
olution peripheral QCT (HR-pQCT) is a new technique that 
can even display the trabecular bone microstructure [57]. 
Bone microarchitecture analysis (BMA) is a new high-res-
olution digital X-ray method in which bone texture analysis 
is performed by means of a fractal algorithm. Although all 
of these techniques provide measures of bone quality, QCT, 
pQCT, and BMA are performed only in highly specialized 
centers and are not recommended for the routine evaluation 
of postmenopausal osteoporosis (grade A recommendation).
Bone quantitative ultrasound (QUS)
Bone quantitative ultrasound (QUS) analyzes the interaction 
between the sound signal and the tissues, providing informa-
tion on bone mechanical properties. It is helpful when pre-
dicting the risk of fracture using low frequencies (200 kHz to 
1.5 MHz) to analyze hand phalanx bones or the heel [58, 59]. 
The parameters analyzed are the speed of propagation (speed 
of sound, SOS), the attenuation wave (broadband ultrasound 
attenuation, BUA), and the amplitude-dependent speed of 
sound (AD-SoS). These parameters define the elasticity/stiff-
ness characteristics of the bone, which are in part related to 
its density [60]. The heel-QUS method can also calculate 
the stiffness index (SI) and the quantitative ultrasound index 
(QUI), parameters derived from the SOS and BUA, which 
seem to be more closely related to the bone properties. When 
using QUS methods, osteoporosis is defined as a T-score 
of less than − 2.5 at the heel and less than − 3.2 at the 
phalanges. QUS can be recommended for epidemiological 
investigations and as a first-level screening tool because of 
its low cost and the fact that it does not require the use of 
ionizing radiation. QUS is a significant predictor of osteo-
porotic fractures but is a weaker predictor than femoral neck 
BMD for hip fractures. In clinical practice, it may be helpful 
to integrate QUS with clinical risk factors for the assessment 
of fracture risk [61] (grade B recommendation).
In Italy, QUS is no longer included in the recently revised 
criteria for reimbursement of antiosteoporotic treatments.
Metabolic evaluation
A biochemical assessment is also recommended for the 
diagnosis and management of osteoporosis and fragility 
fractures. Biochemical assessment is not recommended in 
individuals without fractures who do not have a clinical or 
medical history of secondary osteoporosis and have a low-
est T-score > − 1.0 [39]. Before prescribing a therapy, it is 
always important to discriminate primary from secondary 
forms of osteoporosis. It is a mistake to pursue a therapy 
for osteoporosis without having investigated the etiology 
(grade A recommendation). Osteoporosis may be the only 
manifestation of another disease, such as multiple myeloma 
or other malignant diseases, osteomalacia, primary hyper-
parathyroidism, hyperthyroidism, kidney failure, intestinal 
malabsorption syndromes, idiopathic hypercalciuria, male 
hypogonadism, Cushing’s disease, and other disorders [62]. 
Furthermore, bone loss may be secondary to the use of drugs 
such as glucocorticoids [63], lithium [64], and anticoagu-
lants [65].
Laboratory tests commonly included in an evaluation of 
a differential diagnosis of osteoporosis are classified into 
two groups:
1. First-level exams include:
• Blood cell count
• Erythrocyte sedimentation rate (ESR)
• Serum calcium (corrected for albumin)
• Serum phosphate
• Serum protein electrophoresis
• Serum creatinine
• Alkaline phosphatase
• Urinary calcium (in 24-h urine collection).
In asymptomatic postmenopausal women with osteopo-
rosis, this first screening has been shown to detect more than 
90% of secondary causes of bone loss [43].
2. Second-level exams include:
• Serum 25-hydroxyvitamin D
• Serum thyroid-stimulating hormone (TSH)
• Serum parathyroid hormone (PTH)
• Serum ionized calcium
• Anti-tissue transglutaminase antibodies
• Urinary free cortisol, serum cortisol after 1 mg dexa-
methasone suppression
• Serum testosterone and SHBG (in men)
• Free light chains
• Serum tryptase (or urine N-methylhistamine), fer-
ritinemia
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• Free kappa and lambda light chains
• Bone marrow aspiration and biopsy, and undecalci-
fied iliac crest bone biopsy with double tetracycline 
labeling when biochemical and instrumental evalu-
ation results are inconclusive.
Second-level screening includes analyses/exams that can be 
performed in patients with an extremely high suspicion 
of secondary causes of osteoporosis (Table 3).
Bone turnover markers (BTMs) are used to quantify bone 
remodeling (resorption/new formation cycle). They can be 
used to evaluate the enzymatic activities of osteoblasts, 
osteoclasts, and components released from the bone matrix. 
The levels of the BTMs are therefore proportional to the rate 
of bone remodeling. During life, bone metabolism varies 
in speed and in the balance between resorption and forma-
tion. Bone turnover increases rapidly after menopause: all 
BTMs are high and the loss of bone mass is rapid. Increases 
in resorption markers are associated with an increased risk 
of fracture independent of BMD [66]. Furthermore, BTMs 
are widely used to monitor the antiosteoporotic response to 
therapies in both clinical trials and daily clinical practice. In 
population studies of older women who had sustained a fem-
oral neck fracture, the serum level of C-terminal telopeptide 
(CTX) was found to be five times higher than normal [67]. 
High bone turnover can be an important risk factor for frac-
ture as it increases the loss of bone mass, resulting in micro-
architectural deterioration of bone tissue [68, 69]. Changes 
in BMTs should always be considered in the overall clinical 
judgment for a person suffering from osteoporosis [69].
Bone formation markers are preferentially measured in 
the serum, while bone resorption markers are measured in 
both serum and urine (Ur). They include:
• Bone formation markers (bone alkaline phosphatase, 
osteocalcin, propeptides of procollagen type I (P1NP))
• Bone resorption markers (CTX, NTX, Ur pyridinoline, 
Ur deoxypyridinoline, Ur CTX).
Among these markers, P1NP (a bone formation marker) 
and serum CTX (a bone resorption marker) are the most 
reliable, both at baseline evaluation and in the follow-up.
Although elevated levels of BTMs have been shown to 
predict rapid rates of bone loss in elderly women, these labo-
ratory tests cannot be used to diagnose osteoporosis and/
or used in the clinical routine [70] (grade B recommenda-
tion). Nonetheless, BTMs have proven useful for measuring 
response to drug therapy and improving patient treatment 
compliance [71].
Table 3  Biochemical testing in osteoporosis and associated diagnoses (↑ = increased; ↓ = decreased)
Test parameter Associated condition
Blood count Inflammatory diseases and malignancy
Serum protein electrophoresis and free kappa and lambda light chains Multiple myeloma
ESR ↑ Differential diagnosis of inflammatory causes of vertebral deformities
Serum calcium ↑ Primary hyperparathyroidism or other causes of hypercalcemia
↓ e.g., secondary hyperparathyroidism, malabsorption
Serum phosphorus ↑ Renal insufficiency grade IV
↑ Secondary renal hyperparathyroidism
↓ Malabsorption
Alkaline phosphatase (AP) ↑ Osteomalacia, Paget’s disease
Serum PTH ↑ Hyperparathyroidism
Serum creatinine ↓ Renal osteodystrophy
25-Hydroxyvitamin D3 ↑ Vitamin D intoxication
↓ Vitamin D deficiency, osteomalacia
Urine calcium/24 h ↓ Intestinal malabsorption
↑ Urinary stones
TSH < 0.3 mU/L endogenous or caused by l-thyroxine medication as a risk 
factor for fractures
Testosterone in men Hypogonadism
Anti-tissue transglutaminase antibodies Celiac disease
Urinary free cortisol ↑ Adrenal hypersecretion
Serum tryptase or urine N-methylhistamine ↑ Mastocytosis
Bone marrow aspiration and biopsy and undecalcified iliac crest bone 
biopsy with double tetracycline labeling
Renal failure, vitamin D-resistant osteomalacia, mastocytosis, and rare 
metabolic bone diseases
Bone resorption parameters High bone turnover as a fracture risk
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Genetic evaluation
Genetic components are known to strongly influence bone 
mineral density (BMD) and bone architecture and turnover, 
so they play an important role in determining risk of osteo-
porosis and fragility fractures. Human twin and family link-
age studies as well as animal model studies have confirmed 
the importance of genetic factors in the individual variance 
in peak bone mass acquisition, BMD, bone geometry, and 
metabolism and thus the predisposition to osteoporosis and 
related fragility fractures. Major advances in the knowledge 
of genetic aspects of osteoporosis and fracture risk have 
been made over the last two decades, principally through the 
study of monogenic bone diseases, linkage analyses in osteo-
porotic pedigrees, association case–control and population-
based studies of candidate genes (studies of single genes 
and, more recently, the simultaneous analysis of hundreds of 
genes and their polymorphic variants using next-generation 
sequencing (NGS) techniques), and experimental crosses in 
animal models [72]. Currently, over 100 different common 
polymorphic variants within several genes that are known 
to be involved in bone and mineral metabolism regulation 
have been tested for their association with bone mass and 
other determinants of bone quality and fracture risk. Unfor-
tunately, these studies have often reported inconclusive and/
or contradictory results, and they have demonstrated that 
each individual candidate gene exerts only a relatively mod-
est effect on bone-tissue metabolism and osteoporosis and 
fracture risk. Indeed, it is now well established that osteo-
porosis is a multifactorial complex disorder with a patho-
genesis involving the interactions and synergic effects of 
(1) various predisposing genetic polymorphic variants in 
numerous genes regulating bone and mineral metabolism, 
(2) reversible, highly dynamic, age-, cell-, and tissue-spe-
cific epigenetic mechanisms that regulate the expression 
of these genes (in response to internal and external signals 
and changes), (3) nonskeletal risk factors that can influence 
the risk of falling (i.e., muscle strength, balance, and visual 
acuity), (4) environmental influences, and (5) dietary and 
lifestyle habits [72].
Nonetheless, the identification of genetic polymorphisms 
or epigenetic marks to refine the probability of fracture is not 
currently recommended in clinical practice.
When monogenic bone diseases are suspected, it is rec-
ommended that genetic analyses should be carried out in 
specialized research centers. Indeed, since cases of juvenile 
osteoporosis have been ascribed to inactivating mutations of 
the type 1 collagen (COL1A1), ERalpha (ERα), aromatase 
(CYP19), and low-density lipoprotein receptor-related pro-
tein 5 (LRP5) genes, the sequencing of these genes can be 
performed. When low levels of ALP are detected during 
first-level screening (see the next section), the sequencing 
of tissue nonspecific alkaline phosphatase (TNSALP) is 
recommended to exclude/confirm hypophosphatasia. The 
presence of decreased platelet counts may lead to a suspicion 
of Gaucher disease, and proper genetic screening should be 
performed (acid beta glucosidase, GBA) (grade B recom-
mendation) [72].
Figure 2 summarizes the recommendation statements for 
the diagnosis of osteoporosis in a toolbox.
Clinical risk factors and fracture risk assessment
Clinical risk factors
The pathogenesis of osteoporosis is multifactorial, and frac-
ture risk depends upon several independent risk factors. The 
overall risk of fracture in patients affected by osteoporosis 
derives from factors that predominantly cause a reduction 
in BMD and factors that are completely or partially inde-
pendent of BMD, such as “bone quality” (bone geometry, 
microstructure, and turnover; crystalline and organic com-
position of the matrix) and extraskeletal factors. Many risk 
factors act through different mechanisms simultaneously. A 
low BMD, a medical history of fragility fracture, age, and a 
family history of osteoporosis are risk factors for osteoporo-
tic fracture. Although BMD is used to define the diagnostic 
threshold, the threshold for pharmacological intervention 
and the absolute risk of fragility fracture depend on the 
independent influences of the various risk factors. It has 
been stated that subjects with multiple risk factors are at a 
higher risk of fracture than subjects with a single risk factor, 
including an isolated reduction in BMD. In adult osteopo-
rosis, different factors may directly influence BMD, such as 
gender, calcium intake, physical activity, age of menopause, 
propensity to fall (such as physical disability), environmental 
cues, alcohol consumption, and drugs (e.g., benzodiazepines 
or diureticsor both) and other factors, such as age, smok-
ing, low body weight, vitamin D deficiency. The presence of 
comorbidities increases fracture risk, and genetics have been 
shown to exert a strong influence on BMD and bone micro-
architecture. Several polymorphisms (e.g., estrogen receptor, 
vitamin D receptor, and COLIA1) have been associated with 
a reduction in BMD and an increased risk of fragility bone 
fractures, but overall they account for only 30% of the vari-
ability in BMD and cannot therefore be taken into account 
when defining the risk of fragility fracture, as stated above. 
Table 4 lists the risk factors for osteoporosis and fragility 
fractures, along with their evidence levels [73].
BMD
The BMD depends on peak bone mass and bone loss 
related to menopause and aging, and is influenced by 
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genetic and nutritional factors, life habits, coexisting dis-
eases, and other pharmacologic therapies. The BMD is a 
crucial determinant of fragility fracture risk. Many cross-
sectional and prospective population studies indicate that 
the risk for fracture increases by a factor of 1.5–3.0 for 
each decrease in BMD of a standard deviation [56]. The 
use of bone mass measurements for prognosis depends 
upon the accuracy. Densitometric techniques usually have 
high specificity but low sensitivity, which depend on the 
cutoff chosen to designate high risk. However, although a 
reduction in BMD is an important risk factor for fragility 
fracture, its predictive power increases if it is evaluated 
together with independent factors that provide additional 
data complementary to the BMD.
Age
For both genders, fracture risk is significantly dependent 
on age, and fracture risk approximately doubles with each 
decade. Advancing age contributes to fracture risk indepen-
dently of BMD. The same T-score obtained using the same 
technique at any one site varies in significance with age. For 
any BMD, fracture risk is much higher in the elderly than in 
the young [74, 75]. The association of age with fracture risk 
is probably due to a deterioration in biomechanical factors 
(bone architecture and bone quality), as well as the risk of 
multiple falls, which also increases with age.
Previous fractures
In both sexes, a previous fragility fracture is an important 
risk factor for further fractures. The most recent epide-
miological studies have shown that any previous fracture, 
regardless of location, increases the risk of new fractures 
[76]. The risk also depends on the number of previous frac-
tures. Subjects who have had three or more fractures have a 
roughly tenfold higher risk of new fractures than those who 
have not had fractures, and a two- to threefold higher risk 
than those who have had only a single fracture. In particular, 
single vertebral fractures of grade 1 according to Genant 
(leading to a 20–25% reduction in height) are associated 
with a moderately increased risk (1.5–2 times higher) of 
subsequent osteoporotic fractures. Two or more vertebral 
fractures of grade 1 or one/several fractures of grade 2 or 3 
Fig. 2  Toolbox for guidance: diagnosis of osteoporosis
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according to Genant (leading to a 20–40% and > 40% reduc-
tion in height, respectively) are very severe risk factors for 
further osteoporotic fractures (relative risk of between 2 and 
> 10). In both sexes, nonvertebral fractures after age 50 are a 
moderate risk factor for osteoporotic fractures, independent 
of BMD and age (relative risk before and after adjustment 
is approximately 1.9). Although a previous fracture is often 
related to a low BMD, the risk of new fractures is an inde-
pendent risk factor.
Family history
A family history of fragility fractures influences fracture 
risk independent of BMD. A positive history of osteoporotic 
fractures is regarded as the most reliable prognostic indica-
tor of a genetic risk of osteoporotic fractures. In particu-
lar, a history of femur fractures in the parents significantly 
increases the risk of fractures of the femur and, to a lesser 
degree, of all types of osteoporotic fractures.
Comorbidity
Several pathological disorders are associated with an 
increased fracture risk. In many of these conditions, the risk 
is mediated by the reduction in BMD. Several mechanisms 
are often involved, such as chronic inflammation, impair-
ment of bone quality, the general state of health, decreased 
mobility, decreased muscle mass and strength (sarcope-
nia), and an increased risk of falls. Vitamin D deficiency is 
often considered an additional negative factor. The diseases 
usually associated with an increased fracture risk are rheu-
matoid arthritis, untreated hypogonadism in men and women 
(e.g., premature menopause, bilateral oophorectomy or 
orchidectomy, anorexia nervosa, chemotherapy for breast 
cancer, hypopituitarism, androgen deprivation therapy in 
men with prostate cancer), inflammatory bowel disease (e.g., 
Crohn’s disease and ulcerative colitis), prolonged immobility 
(e.g., spinal cord injury, Parkinson’s disease, stroke, muscu-
lar dystrophy, ankylosing spondylitis), organ transplantation, 
type 1 and type 2 diabetes, thyroid disorders (e.g., untreated 
hyperthyroidism, thyroid hormone suppressive therapy), and 
chronic obstructive pulmonary disease.
Medical treatments
Several drugs have been associated with an increased risk 
of fragility fracture. Among these, glucocorticoid therapy is 
the most common cause of secondary osteoporosis, mostly 
due to factors independent of BMD. Fragility fracture occurs 
in 30–50% of patients receiving long-term glucocorticoid 
therapy [77]. Other drugs, such as adjuvant hormone block-
ing therapy (aromatase inhibitors in women operated on for 
breast cancer, GnRH agonists in men with prostate cancer), 
cause a progressive reduction in BMD, but the involvement 
of independent risk factors is not excluded.
Immobility
Immobility, causing a reduction in BMD due to increased 
bone resorption, is a moderate risk factor for fragility frac-
tures, with a relative risk of 1.5–2. Subjects who are limited 
in their mobility to such an extent that they cannot leave 
their home, do house work, or walk more than 100 m are 
regarded as immobile.
Smoking
Smoking is an independent moderate risk factor for vertebral 
fractures and peripheral fractures in both sexes, with a rela-
tive unadjusted and adjusted risk of approximately 1.2–1.8. 
The dependence on the number of cigarettes has not yet been 
adequately analyzed.
Risk factors for falls
Risk factors for falls play a key role in the occurrence of 
fractures, especially in the oldest age groups. Moreover, over 
80% of nonvertebral fractures are related to falls. The main 
risk factors for falls are musculoskeletal and neuromuscu-
lar impairment, impaired visual acuity, hearing loss, use 
of psychotropic agents, diseases (e.g., Parkinson’s disease, 
dementia, depression, stroke-related impairment, vitamin D 
Table 4  Risk factors for low BMD and fragility/low-energy frac-
tures: levels of evidence are also shown (level 1: evidence from RCTs 
or metanalyses of RCTs; level 2: evidence from prospective cohort 
studies or poor-quality RCTs; level 3: evidence from case–control 
studies or retrospective cohort studies). Reproduced (with permis-
sion) from Table  1 of Guidance for the diagnosis, prevention and 
therapy of osteoporosis in Italy (Cianferotti and Brandi [73])
Risk factor For BMD For fracture
BMD 1 1
Age 1 1
Fragility fractures after 40 years of age 2 1
Family history of fragility fractures 2 2
Chronic corticosteroid therapy 1 1
Premature menopause (< 45 years) 1 2
Weight 1 2
Reduced calcium intake 1 1
Reduced physical activity 2 2
Smoking 2 1
Alcohol 2 3
Risk factors for falls – 1
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deficiency), use of alcohol, sedentary lifestyle, malnutrition, 
and environmental factors.
Targeting risk assessment and risk charts
Despite the fact that a low BMD is still the basis for the 
definition of osteoporosis and the main risk factor for fra-
gility fractures, it should not be considered alone when 
defining the overall risk for fracture and the single interven-
tion threshold. The limitations of assessing bone quantity 
with the BMD have been discussed previously. For a given 
T-score, age increases the risk for fracture [75]. Moreover, 
while the risk for fracture varies markedly among countries, 
the T-score differs only minimally. Therefore, other factors 
may modulate fracture risk. Specific algorithms such as the 
Garvan calculator [78], the QFracture [79], and  FRAX® 
[80], which incorporate several risk factors in addition to age 
(as described above), have been developed to better define 
the risk for fracture and the consequent intervention thresh-
old. Among these tools, the  FRAX® tool [81] has been the 
most extensively employed and validated in postmenopausal 
osteoporosis and in the other main types of osteoporosis. 
 FRAX® is a computer-based calculation tool that calculates 
the individual 10-year probability of major osteoporotic 
fractures (namely at the hip, humerus, wrist, and overt verte-
bral fractures) and hip fractures. It takes into account major 
risk factors such as age, sex, body mass index, history of 
fractures, previous fragility fractures, parental history of hip 
fractures, present tobacco smoking, previous or current long-
term oral glucocorticoids, rheumatoid arthritis, secondary 
osteoporosis, and alcohol abuse as dichotomous variables, 
and includes mortality as a competing risk. Femoral neck 
BMD can be added, where available, to increase the sensitiv-
ity of the algorithm for predicting the risk of fractures. The 
calculation is available and tailored for different regions of 
the world as it utilizes country-specific epidemiological data 
on fracture and death [82, 83].
The  FRAX® tool does, however, have some limita-
tions [84]. The majority of variables are discrete and not 
continuous, lumbar BMD is not taken into account, and 
there is often a discrepancy between the T-score measured 
at the hip and the T-score measured at the lumbar spine. 
Therefore, some authors have proposed adjustments to the 
 FRAX®-derived risk (e.g., adjustments based on the dos-
age of glucocorticoids, and on the difference between the 
T-scores at the lumbar spine and femoral neck) [85, 86].
In the absence of a universally accepted policy in Europe 
for identifying individuals at high risk of fracture by popula-
tion screening, a case-finding strategy is usually employed, 
taking into account the presence of previous or prevalent 
fragility fractures and any significant risk factors [2]. The 
presence of a previous major low-trauma fracture identi-
fies a subject as being at high risk of (re)fracture regardless 
of the BMD measurement (grade A recommendation). In 
countries where the accessibility to DEXA measurement is 
high, albeit regulated by regional reimbursement policies, 
as in Italy, BMD assessment is useful for refining fracture 
risk in cases with  FRAX®-derived intermediate risk (grade 
A recommendation).
Risk charts defining the 10-year probability of major 
osteoporotic fracture are available on the  FRAX® website; 
these are based on country-specific epidemiology data for a 
given BMI (for Italy, see [87].
In Italy, a  FRAX®-derived algorithm called FRAHS was 
recently developed for risk assessment by general practi-
tioners [88], based on the data from a large Italian popula-
tion collected by general practitioners. Other tools, such as 
DeFRA (developed in Italy), have not yet been validated on 
a large scale.
Figure 3 summarizes the recommendation statements for 
osteoporotic fracture risk assessment in a toolbox.
General strategies for the prevention 
and treatment of osteoporosis
Global approaches
Health care systems should be structured to meet the needs 
of the patient in terms of their preferences, values, and 
expectations, particularly in the area of chronic disease [89, 
90].
A patient-centered approach involves a partnership 
between health professionals and patients. For those with 
chronic conditions, such as osteoporosis, it means giving 
them an opportunity to understand their condition and the 
skills needed to optimize the time they invest in maintaining 
good health. This idea is increasingly supported by clinical 
evidence, particularly for chronic conditions such as diabetes 
and arthritis.
People with chronic diseases, including osteoporosis, 
require a global approach to achieve better care. The man-
agement of osteoporosis and fragility fractures, which are 
the most serious complications of the disease, must be mul-
tidisciplinary and comprehensive.
The basic components of the comprehensive approach are 
nutrition, physical activity, behavioral interventions (i.e., sun 
exposure, smoking habits, alcohol intake, falls screening), 
and/or pharmacological treatment in individuals with osteo-
porotic fractures or those at high risk for fractures according 
to the fracture liaison service strategy [91]. This approach 
is useful at all disease stages, from primary prevention in 
childhood and adolescence through subsequent ages and 
stages (where the aim is to achieve and maintain optimal 
peak bone mass and strength), right up to the tertiary pre-
vention of elderly subjects with fragility fractures in order to 
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counteract functional and structural regression [92] (grade 
A recommendation). Several studies have investigated the 
importance of a healthy daily life, an adequate level of physi-
cal activity, a balanced diet, and accurate screening of the 
risk of falls in the management of osteoporotic patients [93].
Adequate dietary intakes of calcium, vitamin D, and pro-
tein contribute to bone and muscle health and thereby reduce 
the risk of fragility fractures.
Physical exercise, assessment of the home for hazards 
(slippery floors, obstacles, insufficient lighting, handrails), 
assessment of visual acuity, withdrawal of psychotropic 
drugs, and a multidisciplinary program to reduce risk fac-
tors represent the core components of the strategy for pre-
venting the first fall and recurrent falls. Resistance exercise 
performed to increase muscle strength may prevent falls, 
improve balance and coordination, and maintain bone 
strength by stimulating bone formation and decreasing bone 
resorption.
Another goal of the global approach to osteoporotic 
patients is to reduce the bone injury caused by the fall 
impact. There are now devices, such as padded hip pro-
tectors, that offer biomechanical protection during a fall, 
decreasing the force of the impact on the bone and thereby 
reducing the incidence of fracture of the proximal femur, 
particularly for high-risk institutionalized elderly individuals 
[94, 95] (grade B recommendation).
Pharmacologic intervention is widely used as the only 
approach for fragility fracture prevention in clinical practice 
despite nonoptimal outcomes; a comprehensive approach is 
considered to be the most suitable management strategy for 
reducing the risk of fracture.
Exercise and fall prevention
Physical activity is any bodily movement produced by 
the contraction of skeletal muscle that increases energy 
expenditure above a basal level. Physical activity can be 
categorized according to mode, intensity, and purpose, and 
includes the following categories: occupational, leisure-time 
or recreational, household, self-care, and transportation or 
commuting activities [96]. Exercise and exercise training is 
defined as planned, organized, and repetitive physical activ-
ity that is frequently used to enhance or maintain physical 
fitness, physical performance, or specific health outcomes 
[97].
Several studies have investigated the timing and effect 
of exercise in increasing bone mass and preventing falls. 
The National Osteoporosis Foundation (NOF) strongly 
endorses lifelong physical activity at all ages, stating that 
proper exercise—particularly regular weight-bearing and 
muscle-strengthening exercises—may improve physical per-
formance/function, bone mass, muscle strength, and balance, 
and can reduce the risk of falling [98].
Exercise has a positive effect on bone health, especially 
during the late childhood and adolescence, which are critical 
periods for skeletal growth and development (grade A rec-
ommendation). In a recent systematic review, Weaver et al. 
[99] found beneficial effects of physical activity, including 
dynamic resistance exercise and jumping performed at least 
3 days per week, on both BMD and bone strength in youth.
In a Cochrane systematic review, Howe et al. [100] 
suggested that combination exercise programs, including 
weight-bearing activities and progressive resistance train-
ing, have a statistically significant positive effect on bone 
density at the spine in postmenopausal women compared 
to individuals that perform their usual activities. However, 
there is no definitive evidence supporting the benefits of 
exercise in women with vertebral fragility fractures [101] 
(grade B recommendation).
The type and amount of exercise that should be per-
formed remain controversial. A systematic review showed 
that, in older adults and elderly individuals, strength exer-
cise is effective for improving or maintaining site-specific 
bone mass, and multicomponent exercise programs includ-
ing resistance, aerobic, high-impact, and/or weight-bear-
ing training may help to prevent age-related bone loss, 
especially in postmenopausal women [102].
Fig. 3  Toolbox for guidance: osteoporotic fracture risk assessment
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In a systematic review, Zehnacker et al. [103] suggested 
that to achieve the best results of resistance exercise in 
postmenopausal women, high-loading, high-intensity 
training for three sessions per week and for two or three 
sets per session is needed. Another recent systematic 
review showed that resistance training alone or in combi-
nation with impact-loading activities is more effective at 
preventing bone loss in middle-aged and older men [104] 
(grade B recommendation).
All of the abovedescribed systematic reviews reported 
that walking is not effective at preventing osteoporosis, 
as it only provides a modest increase in the mechanical 
loads applied to the skeleton. A RCT demonstrated that 
a specific exercise program including a combination of 
weight-bearing exercise with moderate/high intensity and 
slow progressive strength exercises could maintain and 
improve the hip and/or vertebral BMD as well as skeletal 
muscle mass and strength in postmenopausal women and 
in elderly people [105].
Zhao et al. suggested that resistance training was help-
ful for maintaining femoral neck and lumbar spine BMD 
in postmenopausal women. However, a subgroup analysis 
showed that combined protocols integrating resistance train-
ing with high-impact or weight-bearing exercises enhanced 
hip and spine BMD, whereas resistance-alone protocols pro-
duced only nonsignificant preventive effects on postmeno-
pausal bone loss [106].
Zhang et al. [107] demonstrated that individuals receiv-
ing both pharmacological treatment (antiresorptive drugs) 
and exercise had higher lumbar spine BMD than individuals 
treated only with antiresorptive agents.
Physical exercise also reduces fall risk. The NICE guide-
lines 2013 recommend a muscle-strengthening and balance 
program for fall prevention [108]. Indeed, poor muscle per-
formance and balance impairment are the key issues targeted 
in fall prevention programs. However, the Cochrane system-
atic review performed by Howe et al. [109] claimed that 
there is insufficient evidence to draw conclusions about the 
effects of exercise and physical activity programs  (mixed 
exercise training of moderate intensity, resistance exercise, 
gait, balance, and functional training) on the risk of falls in 
older people.
On the other hand, in a Cochrane systematic review of 
60 RCTs, multifactorial interventions (e.g., supervised per-
turbed gait exercises on a treadmill and balance training 
using computerized visual feedback programs) performed 
in hospitals significantly reduced the rate of falls, but there 
is no evidence for a reduced risk of falling [110].
Furthermore, a home hazard assessment and interven-
tion, vision evaluation, and referral medication review to 
define the risk of falls in elderly individuals is necessary 
[111–113]. Additional balance intervention could be used 
to reduce the risk of falls. The use of whole-body vibration 
(WBV) could provide a significant improvement in bone loss 
at the lumbar spine in postmenopausal women and could be 
used as a complementary intervention for fall prevention 
[114].
Moreover, a recent RCT demonstrated that tai chi may 
reduce falls and injurious falls in older people more than 
conventional low-exercise training, and that this reduction 
can be maintained for at least 1 year [115].
Nutrition
Nutrition plays a key role in the management of osteoporo-
sis. Daily adequate calcium, vitamin D, and protein intake 
is the preferred option, along with good sun exposure (in 
summer months at a latitude > 37°N). Vitamin D insuffi-
ciency and deficiency are common among older people and 
have detrimental effects on bone health and neuromuscular 
function. Levels of serum 25(OH) vitamin D (the marker of 
vitamin D status) of less than 20 ng/ml are associated with 
mineralization defects. In subjects at high risk for fractures, 
a target of 30 ng/ml should be recommended [116] (grade 
A recommendation).
The use of combined calcium and vitamin D3 supplemen-
tation has been proven to reduce fracture rates in institution-
alized older people. Although there is emerging evidence 
that correction of hypovitaminosis D may reduce propensity 
for falling [111], its relative contribution to fall risk reduc-
tion and the appropriate dosing regimen are uncertain [117].
Supplementation of calcium plus vitamin D was signifi-
cantly related to total and hip fracture risk reduction in both 
community-dwelling and institutionalized middle-aged to 
older adults [93].
In elderly patients with severe hypovitaminosis D 
[25(OH) vitamin D < 10 ng/ml], the administration of chole-
calciferol (vitamin D3) 50,000 IU per week for 8 weeks, or 
the equivalent of 6000 IU per day, followed by a maintenance 
regimen with 1500–2000 IU per day is recommended [118] 
(grade A recommendation). The use of calcifediol (25(OH) 
vitamin D3) is an effective alternative strategy to treat hypo-
vitaminosis D, as demonstrated by the RCT performed by 
Bischoff-Ferrari et al. In that study, the oral administration 
of 20 µg per day (4 drops) or 140 µg weekly of calcifediol 
resulted in a significantly more efficient and rapid increase 
in the serum concentration of 25(OH)D3 and PTH suppres-
sion compared with cholecalciferol [119]. Given the differ-
ent pharmacokinetics and smaller distribution volume, the 
administration of calcifediol should be preferred in condi-
tions characterized by impaired 25-hydroxylation, obesity, 
and malabsorption, and when a rapid correction of vitamin 
D status is needed in order to begin an antifracture treat-
ment [120] (grade B recommendation). Despite the positive 
safety profile of this vitamin D metabolite, the serum dos-
age of calcifediol and the level of urinary calcium should 
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be monitored carefully during supplementation (grade B 
recommendation).
A low calcium intake, especially in young adults, has a 
role to play in the prognosis of osteoporosis. An increase in 
dietary calcium intake through the consumption of calcium-
rich foods (e.g., milk, yogurt, cheese) represents the first step 
to correcting a negative calcium balance. The recommended 
intake of calcium (RNI) is at least 1000 mg daily and 800 IU 
of vitamin D per day in men and women over 50 years. Dairy 
products that are fortified with calcium and vitamin D and 
provide at least 40% of the RNI of calcium (400 mg) and 
200 IU of vitamin D per portion are valuable options (e.g., 
yogurt or milk) [2, 116] (grade A recommendation). When 
dietary sources are not sufficient to provide daily require-
ments, calcium supplements can be administered [121] 
(grade A recommendation).
Caloric intake decreases with age, as does protein intake. 
It has been established that dietary proteins have a direct 
effect on key regulatory proteins and growth factors involved 
in muscle and bone growth, such as mammalian target of 
rapamycin (mTOR) and insulin-like growth factor-I (IGF-I). 
Branched-chain amino acids lead to the activation of mTOR 
and aromatic amino acids (which are particularly prevalent 
in dairy proteins), causing increased IGF-I, which results in 
greater muscle mass and strength. Protein intake has a posi-
tive impact on bone health at all ages [93]. A meta-analysis 
demonstrated a positive association between protein intake 
and BMD, BMC, and a reduction in bone resorption mark-
ers [122].
Moreover, combined protein supplementation and resist-
ance exercises resulted in greater gains in muscle mass and 
strength. The recommended average daily intake of protein 
is at least 1.0–1.2 g/kg/BW, including at least 20–25 g of 
high-quality protein (such as protein supplied by dairy prod-
ucts) with each main meal (breakfast, lunch, dinner) during 
the day [121] (grade A recommendation). Recently, it was 
hypothesized that not only vitamin D but also other vitamins 
and minerals might play a role in maintaining bone health, 
although there are contrasting data in this context [123]. An 
inadequate intake of other micronutrients may contribute to 
the progressive age-related loss of muscle mass and strength 
in the elderly [124]. A recent scoping review provided a 
small amount of evidence supporting the use of micronutri-
ents for healthy aging. In particular, beta-alanine, calcium, 
creatine, fluorides, leucine, magnesium, omega-3 fatty acids, 
potassium, vitamin B6, vitamin B9, vitamin B12, vitamin 
C, vitamin D, vitamin E, vitamin K2, and zinc can maintain 
or improve muscle strength and bone mass [125] (grade B 
recommendation).
Particular approaches in high‑risk groups
Patients at high risk of fragility fractures and falls include 
those with comorbidities such as Parkinson’s disease (PD), 
multiple sclerosis (MS), or neuromuscular disease (NMD), 
which might impair muscle and bone health [126]. A recent 
review investigated bone loss in patients with PD and 
observed a lower BMD in those patients than in age-matched 
controls. Both reduced bone mass and frequent falls may 
explain the increased fracture risk in these patients [127]. 
However, the efficacy of balance exercise at preventing frac-
tures in PD patients is not supported by sufficient evidence 
[128]. Osteoporosis and fractures are also a major cause 
of morbidity in patients with MS. Early intervention can 
improve their bone health and decrease fracture risk. Osteo-
porosis should be treated with a comprehensive approach 
that includes lifestyle changes, increasing physical activity, 
optimizing serum levels of 25(OH)D3 and calcium intake, 
and the use of antiresorptive therapy. Resistance training 
might also be useful for increasing bone and skeletal muscle 
strength, improving balance, and reducing the risk of falls in 
patients with MS [129].
Neuromuscular diseases such as Duchenne and Becker 
muscular dystrophies are characterized by reduced muscle 
mass and strength, which can lead to significant bone loss 
[130]. No guidelines regarding the appropriate treatment of 
bone involvement in these conditions are currently available, 
and it would be desirable to treat these patients as well as 
postmenopausal women.
Individuals with a history of recent fracture should also 
be considered at high risk of a new incident fragility frac-
ture. This category of osteoporotic patients has recently been 
denoted “individuals at an imminent risk of fracture.”
It is now recognized that the number of reported falls is 
more predictive of limb fractures than a low BMD [131]. 
Management of the risk of falls is the first step in the 
detection of patients at a high risk of fracture. The use 
of padded hip protectors may reduce the risk of fragility 
fracture in subjects at a high risk of falls. A recent review 
underlined that hip protectors, when correctly worn, can 
decrease hip fracture risk and both morbidity and mor-
tality in the elderly, especially in institutionalized indi-
viduals [132]. However, a Cochrane systematic review 
demonstrated that there was little evidence that the use 
of hip protectors reduces the incidence of hip fracture in 
older people in institutional settings; it had little or no 
effect on falls and adverse events (skin irritation). Nev-
ertheless, the current best evidence suggests that the use 
of hip protectors may slightly increase the risk of pelvic 
fracture [133] (grade B recommendation).
Figure 4 summarizes the recommendation statements 
regarding general strategies for the prevention and treat-
ment of osteoporosis as a toolbox.
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Pharmacologic treatment
Together with the general guidelines described above, 
pharmacologic treatment must be undertaken in order to 
decrease the risk of fracture in individuals at high risk.
Age‑dependent thresholds for intervention
A history of a previous major low-trauma fracture/fractures 
or the presence of a prevalent vertebral fracture/fractures 
as assessed by vertebral morphometry identifies subjects 
requiring treatment independent of a BMD assessment 
(grade A recommendation).
In women without prior fragility fractures, and when 
a BMD assessment is widely available (as it is in most 
areas of Italy, depending on regional exemption policies), 
BMD assessment by DEXA can be employed to further 
refine the risk for fracture. The 10-year probability of 
major osteoporotic fracture and the threshold for treat-
ment in women without prior fragility fractures with one 
or more risk of fracture are shown in Fig. 5. According to 
this, treatment can be recommended for postmenopausal 
women when the fracture probability as calculated by 
FRAX exceeds the intervention threshold at a given 
age (grade A recommendation). In fact, the intervention 
threshold depends greatly on age. In older subjects it is 
almost equal to 20%, while it appears to be less than 5% 
in younger subjects [2].
In areas with only limited access to DEXA, or in the 
absence of criteria leading to an exemption from the fee 
for DEXA, FRAX calculated without BMD can be used 
to define the fracture probability at which to assess BMD 
and intervene with pharmacologic treatment. In subjects 
where the calculated risk lies within the intermediate 
area, it is advisable to assess BMD in order to better 
refine the 10-year probability risk [2].
Approved drugs for postmenopausal osteoporosis 
and indication for treatment
Approved drugs for the treatment of postmenopausal osteo-
porosis include antiresorptives such as bisphosphonates, 
denosumab, and selective estrogen receptor modulators 
(SERMs), the proformative agent teriparatide, and the 
Fig. 4  Toolbox for guidance: general strategies for prevention and treatment
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antiresorptive/proformative compound strontium ranelate. 
All these therapies have been shown to reduce the risk for 
vertebral fractures, while some of them also reduce the risk 
for nonvertebral fractures, including hip fractures (Table 5) 
(grade A recommendation).
Bisphosphonates
Bisphosphonates (BPs) are analogs of inorganic pyrophos-
phate and inhibit bone resorption. They are able to block 
osteoclastic activity through a mechanism of action that 
depends on the presence or absence of an amino group. 
All bisphosphonates developed so far for the treatment of 
skeletal diseases are able to reduce bone turnover in a dose-
dependent manner with proportional increases in bone den-
sity and to decrease fracture risk (grade A recommendation). 
Bisphosphonates (BPs) are poorly absorbed (0.5–5%) in the 
gastrointestinal tract. BPs are contraindicated in patients 
with hypocalcemia, gastrointestinal disease, and renal 
impairment (serum creatinine above 200 μmol/l or creatinine 
clearance below 30 ml/min), and in those who are pregnant 
or lactating (grade A recommendation).
The BPs that are currently registered in Europe (and in 






• Zoledronate (zoledronic acid).
Etidronate and clodronate are bisphosphonates that lack 
an amino group. In menopausal women, these drugs increase 
spine BMD and maintain a stable femoral neck BMD. The 
recommended dose of etidronate is suboptimal in order to 
avoid negative effects on bone mineralization. Clodronate 
has proven to be effective at reducing clinical fractures at 
Fig. 5  a Assessment of fracture risk in postmenopausal women when 
DEXA is widely available. b Assessment of fracture risk in postmen-
opausal women when access to DEXA is limited (reproduced from 
[2])
Table 5  Approved drugs for postmenopausal osteoporosis. Repro-
duced (with permission) from Table 6 of the Guidance for the diag‑
nosis, prevention and therapy of osteoporosis in Italy (Cianferotti and 
Brandi [73])
Each number in a table cell is the level of evidence for the effect of 
the drug on BMD or fracture risk (fx) at a particular site
a No longer recommended because of side effects
b Also determined by strontium high-molecular weight per se
c As demonstrated by post hoc analyses
Drug BMD Vertebral fx Nonvertebral fx Hip fx





Ibandronate 1 1 1c
Risedronate 1 1 1 1
Zoledronate 1 1 1 1
Teriparatide 1 1 1
PTH1-84 1 1
Strontium ranelate 1b 1 1 1c
ERTa 1 1 1 1
Raloxifene 1 1
Bazedoxifene 1 1
Denosumab 1 1 1 1
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a dose of 800 mg/day per os. Parenteral administration is 
also possible for clodronate (100 or 200 mg/every 15 days 
intramuscularly), but a similar efficacy at reducing fractures 
of the i.m. form has not been demonstrated by comparative 
studies [134]. For these reasons, etidronate and clodronate 
are second-choice drugs for the treatment of osteoporosis.
For alendronate and risedronate, there is documenta-
tion of broad-ranging efficacy in the prevention of vertebral 
and nonvertebral fractures (including hip fractures), with 
a reduction in fractures of about 40–50% in 3 years. The 
antifracture effectiveness of these two drugs has been dem-
onstrated upon daily administration.
In postmenopausal women with osteoporosis, alendronate 
10 mg daily has been shown to reduce vertebral, nonverte-
bral, and hip fractures. Approval for a 70 mg once-weekly 
formulation of alendronate was granted on the basis of a 
bone mineral density bridging study [135]. Recently, alen-
dronate became available as an oral solution to be adminis-
tered once weekly (70 mg) in order to decrease side effects 
and maximize absorption. Recent data indicate that the use 
of proton pump inhibitors in combination with oral bispho-
sphonates may reduce antifracture effectiveness.
Risedronate 5 mg daily or 35 mg once weekly by mouth 
is also approved for the treatment of postmenopausal osteo-
porosis (to reduce the risk of vertebral fracture) as well as 
for the treatment of established postmenopausal osteoporosis 
(to reduce the risk of hip fracture). In a large population of 
elderly women, risedronate significantly decreased the risk 
of hip fracture, an effect that was greater in osteoporotic 
women. Approval for the 35 mg once-weekly formulation 
and for the 75 mg × 2 monthly formulation (administered 
each day for two consecutive days) was granted on the basis 
of a BMD bridging study [136].
Ibandronate was approved on the basis of studies using 
a dose of 2.5 mg/day. At this dosage, the drug is effective 
only at reducing the risk of vertebral fractures. In a post hoc 
analysis of high-risk women (femoral neck BMD T-score 
below − 3.0 SD), a significant reduction in nonvertebral 
fractures was shown. Ibandronate was subsequently mar-
keted at a dose of 150 mg/month (oral administration) or 
3 mg i.v./3 months. These dosage regimens are approved for 
the treatment of osteoporosis in postmenopausal women at 
an increased risk of fracture [137, 138].
Oral BPs (i.e., alendronate, risedronate, ibandronate) 
should be used with caution in patients with upper gas-
trointestinal disease because of possible side effects. Side 
effects of oral BPs include upper gastrointestinal symp-
toms and bowel disturbance. Alendronate should be taken 
after an overnight fast and at least 30 min before the first 
food or drink (other than water) of the day or any other oral 
medicinal products or supplementation (including calcium). 
Tablets should be swallowed whole with a glass of plain 
water (~200 ml) while the patient is sitting or standing in 
an upright position. Patients should not lie down for 30 min 
after taking the tablet.
Zoledronate (zoledronic acid) (5 mg/i.v./year) was regis-
tered for treatment on the basis of a study that clearly docu-
mented an effect on the risk of vertebral, nonvertebral, and 
hip fracture after 3 years of treatment. A study of an exten-
sion of the treatment to 9 years showed that the bone mass 
values at the femoral level remained stable. Nevertheless, 
there were no significant differences in BMD, bone turnover 
markers, and new fracture incidence from the group that dis-
continued treatment 6 years previously. The drug has proven 
itself able to reduce the risk of new clinical fractures and 
mortality when administered 2 weeks after a hip fracture 
[139]. Side effects of zoledronic acid include an acute phase 
reaction (see above), usually only after the first infusion, and 
gastrointestinal symptoms. An increase in atrial fibrillation, 
reported as a serious adverse event, was also seen in the 
main phase III trial, although this finding has not been rep-
licated in other trials involving zoledronic acid. Zoledronic 
acid is given as an intravenous infusion over a minimum 
period of 15 min.
Because of concerns over possible adverse effects of 
long-term bisphosphonate therapy (i.e., osteonecrosis of 
the jaw (ONJ) and atypical fractures), the need to continue 
treatment should be reviewed at regular intervals.
Based on the available data, it is recommended that the 
risk should be reassessed after 5 years for alendronate, rise-
dronate, or ibandronate and after 3 years for zoledronic acid. 
In patients at a high risk of fracture, a continuation of treat-
ment without the need for further assessment can generally 
be recommended (grade A recommendation).
Withdrawal of treatment from alendronate, ibandronate, 
or risedronate is associated with decreases in BMD and 
increased bone turnover after 2–3 years for alendronate and 
1–2 years for ibandronate and risedronate. When treatment 
is discontinued after 3 years of zoledronic acid therapy, 
the beneficial effects on BMD continue for at least another 
3 years. For most treated individuals, the treatment should 
be stopped after 3 years, and the case for continuation of 
therapy reviewed 3 years later. Individuals with a previ-
ous vertebral fracture or a pretreatment hip BMD T-score 
≤ − 2.5 SD may be at increased risk of vertebral fracture if 
treatment is stopped [140].
Denosumab
Denosumab is a humanized monoclonal antibody capable 
of neutralizing RANKL, a cytokine that interacts with the 
RANK receptor on the membrane of pre-osteoclasts and 
mature osteoclasts. In this way, it affects osteoclast recruit-
ment, maturation, and survival. Subcutaneous administration 
is followed by a reduction in osteoclastic bone resorption 
and, subsequently, a reduction in neoformative activity; for 
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this reason, it is an antiresorbitive drug, like bisphospho-
nates. The most significant differences from BPs are (a) the 
effect, which ceases immediately upon the disappearance 
of the drug from circulation (therefore, if treatment is dis-
continued and the patient is still at a high risk of fracture, a 
rapid re-evaluation to consider whether to start an alterna-
tive treatment is recommended), (b) its uniform action on 
all skeletal structures irrespective of bone turnover, which 
results in greater pharmacological activity in the cortical 
bone, and (c) that chronic therapy is associated with a con-
tinuous densitometric increase, in contrast to what happens 
with other antiresorptive drugs, which plateau in BMD after 
3–4 years of therapy, particularly at the cortical level.
Denosumab is approved for the treatment of osteoporosis 
in postmenopausal women at increased risk of fracture, and 
is given as a subcutaneous injection of 60 mg once every 
6 months. In postmenopausal women, the antifracture effec-
tiveness has been documented for vertebrae (− 68% after 
3 years of therapy), femur (− 40% after 3 years of therapy), 
and nonvertebral sites (− 20% after 3 years of therapy). 
Denosumab has also demonstrated antifracture efficacy in 
women with breast cancer treated with aromatase inhibitors 
and in men under antiandrogen treatment for prostate cancer. 
In the most severe forms of osteoporosis, an additional BMD 
gain has been documented when denosumab is combined 
with teriparatide in the sequence teriparatide–denosumab 
but not vice versa [141].
Like BPs, denosumab is contraindicated in women with 
hypocalcemia or hypersensitivity to any of the constituents 
of the formulation. Its use is not recommended in preg-
nancy or in the pediatric population (age ≤18 years). No 
dose adjustment is required in patients with renal impair-
ment. The safety and efficacy of denosumab in patients with 
hepatic impairment have not been studied. Hypocalcemia 
should be corrected and prevented by ensuring an adequate 
intake of calcium and vitamin D before initiating therapy. 
Side effects include skin infection, predominantly celluli-
tis, and hypocalcemia. Hypocalcemia is an identified risk in 
patients treated with denosumab, and one that increases with 
the degree of renal impairment. Pre-existing hypocalcemia 
must be corrected prior to initiating therapy. An adequate 
intake of calcium and vitamin D is important in all patients, 
especially in those with severe renal impairment. Monitor-
ing of calcium levels and an assessment of calcium intake 
should be conducted prior to each dose of denosumab and 
within 2 weeks after the initial dose in patients predisposed 
to hypocalcemia (e.g., patients with severe renal impairment, 
creatinine clearance < 30 ml/min), or if suspected symp-
toms of hypocalcemia occur, or if otherwise indicated (grade 
A recommendation). Patients should be advised to report 
symptoms of hypocalcemia.
Potential adverse events of antiresorptive therapy: 
osteonecrosis of the jaw (ONJ) and atypical fractures
Antiresorptive therapy for malignant diseases (bone metasta-
ses, malignant hypercalcemia, etc.) in doses ten times higher 
than those used for the management of osteoporosis is asso-
ciated with an increased risk (up to 1%) of osteonecrosis of 
the bones of the oral cavity (ONJ), ascribed to osteomyelitis 
due to Actinomyces infection. This event occurs very rarely 
in patients (1:10,000 treated patients) receiving bisphos-
phonate or denosumab therapy at the regimens commonly 
employed in osteoporosis [142]. For subjects treated with 
bisphosphonates for osteoporosis for less than 3 years who 
do not have individual risk factors (diabetes, immunosup-
pression, steroids, smoking, alcohol), the risk of ONJ for 
invasive procedures is extremely low. In the case of sur-
gery in the oral cavity (extraction), a broad-spectrum anti-
biotic therapy is mandatory in order to prevent bone infec-
tion (grade B recommendation). Many guidelines suggest 
the discontinuation of BPs for a period of 3 months and 
the recovery of the drug upon the healing of the surgical 
wound. There is no evidence that this actually reduces the 
risk of ONJ in view of persistent pharmacological effects 
of bisphosphonates. For the same reason, moreover, the 
suspension of bisphosphonate for a relatively short period 
of time (1/2 months) probably does not compromise the 
effectiveness of the therapy for osteoporosis. The Ministry 
of Health has recently produced a document concerning 
ONJ associated with the use of BPs on both oncological 
and osteoporotic patients under the auspices of the Society 
of Maxillofacial Surgery and Pathology and Oral Medicine 
(SICMF and SIPMO). It should be stressed that many of the 
recommendations derived from the literature and present 
in many international guidelines have a relatively low level 
of evidence but a relatively high recommendation based on 
expert consensus. All patients should be evaluated for ONJ 
risk factors prior to antiresorptive treatment, and a dental 
examination with appropriate preventive dentistry should be 
considered prior to treatment in patients with concomitant 
risk factors. Patients should be encouraged to maintain good 
oral hygiene practices, receive routine dental check-ups, and 
immediately report any oral symptoms such as dental mobil-
ity, pain, or swelling during treatment. While undergoing 
treatment, these patients should avoid invasive dental proce-
dures if possible, but bisphosphonate or denosumab therapy 
should not be regarded as a contraindication for necessary 
dental treatment. In the vast majority of patients, the benefits 
of treatment outweigh the risks (grade A recommendation).
Atypical fractures, mainly of the subtrochanteric and dia-
physeal regions of the femoral shaft, have been reported in 
patients on long-term therapy with bisphosphonates or deno-
sumab on rare occasions. In patients treated with BPs for 
many years (as well as in patients with no previous exposure 
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to bisphosphonates), the appearance of atypical (transverse) 
subtrochanteric femoral fractures was reported. The inci-
dence of these fractures during long-term BP therapy is 
very low (3.2–50 cases per 100,000 person-years), but they 
are clearly linked to the duration of therapy. Based on the 
data available and due to the rarity of these events, the ben-
efits of antiresorptive therapy outweigh the risk. In order 
to minimize the risk of subtrochanteric fracture in patients 
treated with bisphosphonates, the following may be useful: 
(a) consider periods of “therapeutic vacation” after careful 
consideration of the benefit–risk ratio, and (b) monitor and 
correct other risk factors for atypical fracture (chronic use 
of corticosteroids, hypovitaminosis D, chronic use of proton 
pump inhibitors, the presence of several skeletal diseases, 
osteoporosis) (grade B recommendation).
During bisphosphonate or denosumab therapy, patients 
should be advised to report any unexplained thigh, groin, or 
hip pain; if such symptoms develop, imaging of the femur 
(X-ray, isotope scanning, or MRI) should be performed. If 
an atypical fracture is present, the contralateral femur should 
also be imaged (grade A recommendation).
Discontinuation of bisphosphonate or denosumab therapy 
should be considered in patients who develop an atypical 
fracture, and alternative treatment options should be consid-
ered where appropriate. Surgical treatment with intramedul-
lary nailing is often recommended.
Selective estrogen receptor modulators (SERMs)
SERMs are synthetic compounds that bind to the receptor 
for estrogen and produce agonistic effects in bone and liver 
but antagonistic effects at the level of the breast and geni-
tourinary tract.
The SERMs that are currently approved in Italy for the 
prevention and treatment of osteoporosis are raloxifene and 
bazedoxifene [143]. They are contraindicated in women 
with childbearing potential, a history of venous thrombo-
embolism or unexplained uterine bleeding, liver and kidney 
failure, or climacteric symptoms.
Raloxifene is a selective estrogen receptor modulator that 
inhibits bone resorption. It is approved for the treatment and 
prevention of osteoporosis in postmenopausal women at a 
dose of 60 mg daily. It has been shown to reduce vertebral 
fracture risk but reductions in nonvertebral and hip fractures 
have not been demonstrated.
Bazedoxifene is able to prevent loss of bone mass at a 
dose of 20 mg/day in normal and osteopenic women. In 
women with osteoporosis, the risk for vertebral fracture 
was significantly reduced (by 42%). Extending the study to 
5 years demonstrated the persistence of the effect on ver-
tebral fractures (a 32% risk reduction). A post hoc assess-
ment in high-risk patients allowed the demonstration of a 
significant risk reduction for nonvertebral fractures for both 
3 and 5 years. In addition, bazedoxifene showed a greater 
antiestrogenic effect in the uterus in the absence of signifi-
cant side effects.
Conversely, estrogen therapy is no longer indicated for 
osteoporosis therapy or the prevention of osteoporosis.
Teriparatide
Teriparatide is the active fragment (recombinant human PTH 
1–34) of parathyroid hormone. During the first 12 months of 
teriparatide therapy, it markedly stimulates bone formation; 
this period is therefore termed the “anabolic window” of 
teriparatide. It is administered as a subcutaneous injection at 
a dose of 20 μg/day, and the duration of treatment is limited 
to 24 months. The effect on trabecular BMD is significantly 
greater than that obtained with bisphosphonates, with an 
increase in vertebral BMD at 18 months of close to 10%. 
In addition, teriparatide induces an improvement in certain 
geometric features of cortical bone related to resistance to 
fracture. It is approved for the treatment of osteoporosis 
in postmenopausal women at a high risk of fracture and is 
given as a subcutaneous injection at a dose of 20 μg/day 
(grade A recommendation). Teriparatide is also approved 
for the treatment of osteoporosis associated with systemic 
glucocorticoid therapy in women with an increased risk of 
fracture. The duration of treatment is limited to 24 months. 
It has been shown to reduce the frequency of vertebral and 
nonvertebral fractures in postmenopausal women with osteo-
porosis, but there does not appear to be any data on hip 
fractures [144].
Teriparatide is contraindicated in patients with hypercal-
cemia, hyperparathyroidism, severe renal impairment, prior 
radiation to the skeleton, and malignant disease affecting 
the skeleton. It should be used with caution in patients with 
moderate renal impairment. Side effects include headache, 
nausea, dizziness, and postural hypotension.
Strontium ranelate
Strontium ranelate is a molecule that contains two atoms of 
strontium linked to ranelic acid. Treatment with strontium 
ranelate is effective at reducing the risk of vertebral, non-
vertebral, and hip fractures in women with postmenopau-
sal osteoporosis. Strontium ranelate has been evaluated in 
two clinical trials with durations of 5 years—with the main 
analysis carried out after 3 years—involving more than 7000 
women. The results at 3 years showed that the drug reduced 
the risk of vertebral, nonvertebral, and hip fractures (in a 
high-risk subgroup) by 41, 16, and 36%, respectively. The 
results at 5 years confirmed the results observed in the first 
3 years. The drug modestly increases bone formation mark-
ers (ca. 15%) while simultaneously reducing those of bone 
resorption (10–15%) [145, 146].
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Treatment with strontium ranelate leads to a mod-
est change in bowel habits and is associated with a slight 
increase in thromboembolic risk, particularly in elderly 
patients. The drug is contraindicated in patients with current 
or previous venous thromboembolism (VTE), and in patients 
who are temporarily or permanently immobilized. The need 
to continue treatment in patients who are > 80 years old and 
at risk of VTE should be reevaluated. Rarely, serious skin 
allergic reactions to this drug have been reported, some-
times associated with potentially fatal systemic symptoms 
(e.g., drug reaction with eosinophilia and systemic symp-
toms (DRESS); Stevens–Johnson syndrome; toxic epidermal 
necrolysis). In such cases, the drug must be immediately and 
permanently suspended (EMA/185,175/2012).
In a post hoc analysis, treatment with strontium ranelate 
was also associated with an increased risk of myocardial 
infarction in a subgroup of patients with an increased base-
line cardiovascular risk (relative risk compared to placebo 
group: 1.6 (95% CI [1.07; 2.38]).
For the above reasons, the use of this drug is now 
restricted to severe osteoporosis in postmenopausal women 
and men at a high risk of fracture who cannot be treated 
with other approved drugs. It should not be used in patients 
with an established, current, or past history of ischemic heart 
disease, peripheral arterial disease, and/or cerebrovascular 
disease, or those with uncontrolled hypertension (grade A 
recommendation).
Approved drugs for male osteoporosis and indication 
for treatment
Alendronate, risedronate, zoledronate, teriparatide, deno-
sumab, and strontium ranelate are approved drugs for the 
treatment of male osteoporosis in Europe.
BPs are able to increase bone mass at the spine and the hip 
and reduce the risk of vertebral fracture in male idiopathic 
osteoporosis and glucocorticoid-induced osteoporosis. Rise-
dronate is also indicated for the treatment of osteoporosis in 
men at a high risk of fracture. Zoledronic acid has also been 
demonstrated, for the first time, to reduce the risk of clinical 
fracture and mortality when given to patients shortly after 
their first hip fracture (grade A recommendation).
Denosumab is indicated for male idiopathic osteoporo-
sis and iatrogenic osteoporosis due to androgen deprivation 
therapy in prostate cancer. Indeed, it is able to increase the 
BMD in males at a high risk of fracture and is indicated in 
the treatment of bone loss in subjects on androgen depriva-
tion therapy for prostate cancer (grade A recommendation).
Teriparatide is indicated in severe osteoporosis or 
when new vertebral or hip fractures occur during treat-
ment with other approved drugs for osteoporosis (grade A 
recommendation).
The safety profile of these drugs and their effects are 
comparable with the incidence and type of adverse events 
recorded in post-menopausal female population [147].
Treatment of glucocorticoid‑induced osteoporosis
Chronic exposure to excess exogenous or endogenous 
glucocorticoids is an important cause of osteoporosis and 
fractures. Glucocorticoids stimulate bone resorption and 
reduce bone formation by inhibiting the proliferation and 
differentiation of osteoblasts and promoting the apopto-
sis of osteoblasts and osteocytes. Moreover, they alter the 
calcium balance, reducing intestinal absorption, increas-
ing renal excretion, and reducing the secretion of andro-
gens and estrogens, especially pituitary gonadotropins. 
Bone loss caused by glucocorticoid treatment starts early 
(in the first few weeks) and is more pronounced in the first 
6–12  months, especially at the trabecular bone (spine) 
level, with an increased risk of low-trauma fractures. Fra-
gility fractures occur in 30–50% of patients within the first 
5 years of chronic glucocorticoid therapy. The probability 
of fracture is further increased if additional risk factors are 
present in the same subject. The International Osteoporosis 
Foundation and the European Society of Calcified Tissues 
have published a framework for the development of national 
guidelines for the management of glucocorticoid-induced 
osteoporosis (GIO) in men and women aged 18 years and 
over in whom continuous oral glucocorticoid therapy is 
considered for 3 months or longer [148]. Alendronate, rise-
dronate, zoledronic acid, and denosumab are approved for 
the prevention of fractures during chronic treatment with 
glucocorticoids or when chronic treatment with glucocor-
ticoids lasting more than 3 months is planned (prednisone 
equivalent dose ≥ 5 mg/day) (grade A recommendation). 
Teriparatide is the optimal choice in patients  with estab-
lished major fragility fractures who are receiving long-term 
glucocorticoid treatment (grade A recommendation).
Treatment of osteoporosis in patients with CKD 
and after transplantation
Patients with chronic kidney disease (CKD) who are 
undergoing hemodialysis show an incidence of hip fracture 
that is threefold higher than that for the general popula-
tion. Vertebral fractures occur in 50% of subjects receiving 
periodic hemodialysis. Mortality in the first year after hip 
fracture doubles with respect to the general population.
In subjects with CKD stage 1–3, alendronate, rise-
dronate, teriparatide, and denosumab prevent fragility 
fracture with the same degree of efficacy and safety as 
for subjects with normal renal function. Bisphosphonates 
and teriparatide have not been adequately investigated in 
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subjects with CKD stages 4–5 and 5D, and are generally 
contraindicated in cases of stage IV CKD (creatinine clear-
ance below 30 ml/min) (grade A recommendation). Deno-
sumab can be administered even to patients with advanced 
renal failure. Preliminary studies have demonstrated its 
efficacy in a group of patients with CKD stage 4, but it has 
not been possible to draw any definitive recommendations 
so far (grade C recommendation). The progressive deterio-
ration in renal function induces a significant decrease in 
the active metabolite of vitamin D, i.e., calcitriol, resulting 
in increased levels of parathyroid hormone. In subjects 
with CKD stages 4–5 and 5D with elevated parathyroid 
hormone, calcitriol and its analogs are able to reduce the 
levels of parathyroid hormone and favorably modify the 
alterations in bone metabolism (grade A recommendation). 
Treatment with cholecalciferol is able to consistently and 
significantly reduce the levels of parathyroid hormone in 
subjects with CKD stages 1–5 and 5D [149].
In organ transplantation, long-term immunosuppressive 
and glucocorticoid therapies that are usually commenced 
at high doses soon after the procedure greatly increase 
the risk of fragility fracture in these patients. Data show 
a prevalence of fragility fractures of 10–15% in patients 
waiting for an organ transplant (kidney, heart, liver, or 
lung), with an increase in prevalence after transplantation 
of up to 50%.
Alendronate, pamidronate, ibandronate, and zoledronic 
acid have been shown to increase bone mass in the absence 
of significant adverse events and, in particular, without 
inducing any alteration in renal function in patients with 
mild renal impairment after renal transplantation. Several 
studies in small cohorts of patients have shown that the 
administration of intravenous ibandronate, pamidronate, and 
zoledronic acid has a prophylactic effect regarding vertebral 
fractures in the absence of significant side effects, without 
incurring substantial variations in kidney function (grade C 
recommendation). Hypovitaminosis D is present in about 
80% of patients with organ transplantation, and treatment 
with cholecalciferol and calcidiol is strongly recommended 
using schemes and dosages employed in the general popula-
tion [150] (grade A recommendation).
Treatment of juvenile osteoporosis
There is no officially approved treatment for patients with 
IJO. The effect of any kind of medical intervention is dif-
ficult to judge because the disease is rare, has a variable 
course, and is generally believed to resolve without treat-
ment. Some papers report an increase in BMD and clinical 
improvement after treatment with bisphosphonates (grade 
C recommendation).
Bisphosphonate intervention should be restricted to chil-
dren with multiple vertebral crush fractures, who may also 
experience debilitating chronic bone pain [151–153]. Medi-
cal therapies should complement orthopedic and rehabilita-
tive measures such as physiotherapy in all such cases.
Neridronate is the only bisphosphonate registered for 
the treatment of osteogenesis imperfecta. It is also used in 
all forms of IJO, meaning that it is not necessary to resort 
to expensive and not easily accessible genetic evaluations 
(grade B recommendation).
Policy for reimbursement in Italy
In Italy, the Ministry of Health and the Italian Drug Agency 
recently revised the criteria for the prescription and reim-
bursement of antiosteoporotic drugs [154]. Three main cat-
egories were identified:
• Secondary prevention in patients with a history of one 
or more previous fragility fractures at major sites (hip or 
spine) or at minor sites plus T-score < − 3
• Primary prevention in postmenopausal women and men 
over 50 years of age who are undertaking pharmacologic 
treatments that are detrimental to bone health (long-term 
glucocorticoids, antihormonal treatments for mammary 
and prostate cancer) or are at a high risk for fracture 
(T-score < − 4, or T-score < − 3 plus additional risk 
factors).
For secondary prevention, alendronate, risedronate, and 
zoledronate are the first-choice drugs, while denosumab 
and strontium ranelate are the second and third choices, 
respectively. In severe cases (≥ 3 major fractures, or ≥ 1 
major fracture plus T-score < − 4, or ≥ 1 major fracture 
plus chronic glucocorticoids, or ≥ 1 major fracture under an 
approved antiosteoporotic treatment for more than 1 year), 
teriparatide is the first choice. Denosumab is indicated as a 
second-choice drug in the secondary prevention of refrac-
tures, and can be prescribed in the presence of contraindica-
tion or proven side effects of and further fractures under the 
approved first-choice treatment.
For primary prevention, alendronate, risedronate, and 
zoledronate are indicated as first-choice drugs for bone 
protection under chronic glucocorticoid treatment, while 
risedronate or alendronate represent the first-choice drugs 
in patients with T-scores of less than − 4 or less than − 3 
plus a high-risk factor (in this latter case, zoledronate, 
ibandronate, raloxifene, and bazedoxifene are indicated as 
second-choice drugs, and strontium ranelate as the third 
choice).
In addition to alendronate, risedronate, zoledronate, 
and denosumab are the first-choice drugs for patients with 
breast cancer or prostate cancer receiving adjuvant hor-
monal blockade.
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A subsequent change from the first-choice treatment 
could be made in the presence of intolerance, an inability 
to achieve the required intake of the drug, side effects of 
or contraindications for the first-choice drug, or, in the 
case of teriparatide, if the end of the maximum allowable 
treatment period has been reached.
Figure 6 summarizes the recommendation statements 
for the pharmacologic treatment of osteoporosis in a 
toolbox.
Integrated approaches for secondary prevention
Integrated and multidisciplinary approaches for the second-
ary prevention of refracture are strongly advised and are 
needed at all levels of assistance, such as in primary, sec-
ondary, and tertiary care settings. Connections between and 
within these different levels of care must be ensured to opti-
mize the pathways of assistance for osteoporotic patients at 
a high risk of (re)fracture.
Fracture liaison service
The effectiveness of the diagnostic and therapeutic pathway 
described previously increases if it is incorporated within a 
structured program of tertiary prevention. Fracture liaison 
services (FLSs) are systems that are implemented by health 
care systems to prevent secondary fractures  in osteoporotic 
patients (Fig. 7). FLSs were proposed in the framework of a 
project called Capture the Fracture, promoted by the Frac-
ture Working Group of the Committee of Scientific Advisors 
of the International Osteoporosis Foundation (IOF) in 2011 
[155]. They target patients with a fragility fracture because 
approximately 80% of those patients do not undergo screen-
ing for osteoporosis and are not treated with antiosteoporotic 
medications. Moreover, the aim of a FLS is to improve com-
munication between primary care and medical specialists 
and facilitate the approval of care pathways for osteoporo-
sis and treatment for fragility fractures. Primary care physi-
cians, orthopedic teams, and other specialized physicians 
with expertise in fragility fracture prevention are coordi-
nated in a FLS. Such a service also includes a dedicated 
caseworker and a clinical nurse specialist who follows the 
treatment of patients with a fragility fracture. FLSs are based 
in primary or secondary health care settings. Different mod-
els of care have been planned, with the aim of establishing 
an effective method of obtaining recommended standards of 
treatment for osteoporotic fractures.
Evidence suggests that two-thirds of all services that are 
designed to prevent secondary fracture utilize a chief who 
acts as a link between the patient and the health care system 
[156], as this improves the communication between health-
care figures, providing that the patient follows a well-defined 
care pathway.
Fig. 6  Toolbox for guidance: pharmacologic treatment
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Scientific evidence underlines that the FLS concept is 
an established and proven method of preventing secondary 
fragility fractures, following osteoporosis treatment, and 
reducing the overall costs of fracture treatment. Miller et al. 
[156] noted that the strength of the FLS concept is that it 
facilitates patient care by automatically directing subjects 
with a fragility fracture to a healthcare system that is able to 
provide them with the intervention they need and that helps 
them to prevent avoidable fracture-related complications or 
readmission to hospital. Using this approach, patients can be 
treated in greater numbers and those treated show increased 
treatment adherence to treatment, a decreased risk of sec-
ondary fracture, and even reduced mortality over time. The 
core of the FLS program is based on a physician, a FLS 
coordinator, and a nurse. The orthopedic surgeon is also 
located at the core of the FLS, since they are often the first to 
take care of a patient with a fragility fracture and his family, 
and they are the first to explain the link between the fracture 
and osteoporosis  at the time of admission to the hospital. 
The orthopedic surgeon may provide the bridge between the 
patient and the bone specialist, enabling the initiation of 
effective programs of secondary prevention of refracture. 
Patients usually do not consult their primary care physician 
after their fracture has healed, and they often do not require 
further interventions for bone fragility nor antiosteoporotic 
treatment. Aizer et al. [157] reviewed factors contributing to 
the treatment gap in osteoporosis, and suggested that effec-
tive bone health management after a fracture necessitates a 
multimodal approach and requires the recognition of a high 
risk of fracture, effective communication with patients about 
the identification of risk factors for fragility fracture, and 
the importance of patient adherence to treatment regimens. 
Fragility fracture management starts with the identification 
of patients diagnosed with a fragility fracture through bone 
health consultations. Their bone status must be evaluated 
based on their medical history, physical examination, and 
laboratory exams. Recommendations regarding the treat-
ment for osteoporosis—if necessary—are supplied to the 
patient, including calcium and vitamin D supplementation 
and lifestyle modifications. The fragmentation of the care 
path contributes to failure; this is highlighted by the dis-
crepancy between the providers involved in hospitalization 
and those involved in subsequent care management. It was 
demonstrated that only 40% of women over 60 years of age 
with a fragility hip fracture reported an awareness of a diag-
nosis of osteoporosis at their hospital discharge [158]. A 
good FLS model should be based on both a diagnosis of 
osteoporosis made by the orthopedic surgeon at the time of 
the admission for the trauma and the effective communica-
tion of that diagnosis to the patient. This should always be 
followed by recommendations regarding individual fracture 
risk modifications, including pharmacologic and nonphar-
macologic approaches and physical therapy. The latter step 
is represented by a bone health follow-up, ensuring clear 
communication with primary care providers regarding the 
assessment and recommendations for bone fragility treat-
ment. Mitchell et al. [159] remarked how the FLS model 
has been shown to be able to eliminate the care gap in a 
Fig. 7  Model of a fracture liaison service (FLS)
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clinical and cost-effective manner. Indeed, the increase in 
secondary fracture prevention methods leads to a rational 
stepwise pathway to improving health gains. The keywords 
for long-term preventive care are recognition, examination, 
and initiation (of intervention):
• Recognition: the correct recognition of a fragility fracture 
when a patient is admitted to the hospital
• Examination: the evaluation of bone mineral density by 
DEXA examination, and dorsal and lumbar spine X-rays 
for nonvertebral fractures
• Initiation: pharmacologic treatment of osteoporosis, in 
addition to nonpharmacological therapy and falls preven-
tion.
The crucial point is that adherence to osteoporosis treat-
ment has been shown to decrease rapidly in around half of 
the patients who start the treatment, and there is a lack of 
clarity regarding the clinical responsibility for osteoporosis 
treatment [160]. This is because orthopedic surgeons take 
care of the acute phase of the fracture and do not usually 
treat the underlying disease, while primary care physicians 
do not investigate patients who have recently suffered fragil-
ity fractures unless there is a specific recommendation to do 
so by a hospital specialist. Cost-effectiveness analysis of a 
well-organized FLS indicates that there is a large decrease 
in the incidence of secondary hip fracture in the first year. 
Clinical trials confirm the effectiveness of FLS. In particu-
lar, they document a 30% reduction in second fractures and 
a 40% reduction in major fractures (hip, humerus, spine, 
and pelvis) based on a 3-year follow-up in FLS units [161]. 
In addition, a FLS that integrates different specialists can 
provide early diagnosis of psychiatric disease, better psychi-
atric care, and earlier discharge, with a reduction in hospital 
costs and hospitalization length [162]. Compared with pure 
primary care, FLS leads to better compliance with osteo-
porosis treatment. In fact, it seems that it is useful to apply 
the FLS approach when starting and maintaining therapy 
for osteoporosis [163]. In particular, a minimal trauma frac-
ture liaison (MTFL) service significantly reduces the risk of 
refracture by 80%, leading to very high cost-effectiveness 
[164]. Multicenter studies have evaluated patients with a 
recent fragility fracture. Their results have shown that 88% 
of the patients enrolled in a FLS in four Dutch hospitals were 
complying with their osteoporosis treatment at the 1-year 
follow-up, and only 2% of the patients had a subsequent fra-
gility fracture [165]. In the UK, the presence of a FLS leads 
to a high percentage of patients being diagnosed and treated 
for osteoporosis after a hip or proximal humeral fracture. 
The study revealed that 85% of patients with a proximal 
humeral fracture and 20% with a hip fracture underwent a 
DEXA scan [166]. A survey of five large FLSs in the Neth-
erlands highlighted some critical aspects, such as differences 
in the selection of patients and the evaluation of clinical risk 
factors.
In conclusion, evidence suggests that a FLS is useful for 
achieving optimal osteoporosis management and preventing 
secondary fragility fractures, but it needs to be well organ-
ized, and patients should be enrolled in the program when 
they are first admitted to the hospital to treat a fragility frac-
ture (grade A recommendation).
The role of the bone care nurse
The bone care nurse (BCN) is a nurse who has acquired 
advanced knowledge of metabolic bone diseases and specific 
clinical skills to evaluate, plan, and manage people affected 
by osteoporosis [167]. These skills allow the BCN to imple-
ment the optimal paths for the education, diagnosis, treat-
ment, and rehabilitation of osteoporotic patients. BCNs work 
in various care settings in hospitals and communities, such 
as in the areas of prevention, primary care, and rehabili-
tation. BCNs organize and participate in educational cam-
paigns in order to encourage a culture of specific prevention 
through early diagnosis, the appropriate use of diagnostic 
tools to ensure long-term adherence to a proper lifestyle, and 
the proper use of drug therapy. In addition, BCNs with mul-
tidisciplinary teams plan and manage clinical care pathways 
(FLSs) and monitor people at risk for osteoporosis or fragil-
ity fracture through tailored educational intervention [168]. 
In fact, this educational intervention is considered key to 
improving adherence in osteoporotic patients. The relevant 
literature shows that, during follow-up, tailored educational 
intervention along with counseling, motivational interviews, 
and educational programs are more effective than standard 
information at improving the outcomes of osteoporotic 
patients [169]. These tailored educational interventions 
are performed to promote a healthy lifestyle and improve 
adherence to an appropriate diet, regular exercise, and the 
proper use of drug therapy. Nurses should encourage patients 
to stop smoking, ensure their diet includes the appropriate 
nutrition, avoid a sedentary lifestyle, take regular medica-
tion, and spend at least 10–15 min outdoors on sunny days. 
These are all behaviors that will help the patient to maintain 
a healthy lifestyle and improve self-care.
Several studies have shown that decision aids, monitoring 
schedules with nurses, and pharmaceutical care with coun-
seling packages are interventions that improve adherence 
to drug therapy [170–172]. Specifically, three studies used 
interventions involving direct relationships between patients 
and health professionals, such as counseling and telephone 
counseling interventions, to develop therapeutic relation-
ships [173, 174]. In another study, adherence to medication 
was improved when tailored educational intervention led 
by a nurse was included [175]. Four studies showed that 
medication adherence did not improve with delivery to the 
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patient of educational materials such as leaflets, letters, or 
automated telephone calls [176–178]. Three studies that 
focused on the promotion of adequate nutrition and exer-
cise levels showed that it is possible to encourage healthy 
lifestyles through therapeutic lifestyle modification interven-
tion, a tailored intervention with written materials, coun-
seling sessions, and an exercise education program based 
on the transtheoretical change model [179–181]. According 
to the scientific literature, switching to an appropriate diet 
with the proper calcium and vitamin D intake and ensuring 
that a sufficient amount of  physical activity is performed 
are important lifestyle changes that can decrease the risk of 
fracture [182–184]. Moreover, the literature shows that inter-
ventions which focus only on information do not decrease 
risk factors for falls and do not improve adherence to healthy 
lifestyles [185]. In this context, BCNs could play a key role 
in the lives of patients affected by osteoporosis or those who 
have suffered a fragility fracture (grade B recommendation).
Relationship with the primary care system
Despite numerous campaigns promoted by various scientific 
societies, primary care physicians (PCPs) do not yet perceive 
osteoporosis to be a serious disease in the elderly. Previ-
ous studies [164, 166] have shown that, if not directly pre-
scribed at discharge, many patients with a fragility fracture 
do not receive a prescription for diagnostic tests from their 
primary care physician, and antiosteoporotic therapy is often 
not prescribed. The PCP is a fundamental figure in fracture 
risk management. Knowledge of the patient’s comorbidities 
can allow the doctor to identify bone fragility even before 
a fracture occurs.
PCPs recognize and treat osteoporosis rather infrequently, 
for a number of reasons. Usually, osteoporosis is not con-
sidered a particularly important disease in the elderly, or 
important enough that it needs to be addressed in a spe-
cific visit. Furthermore, physicians have the opportunity to 
record medications but they may not consider supplements 
that do not need a prescription, such as calcium and vitamin 
D. Osteoporosis is an asymptomatic disease that is difficult 
to diagnose in the absence of fracture. When fractures occur, 
patients are often treated for the fracture, but only rarely is 
the trauma mechanism investigated. If the orthopedic sur-
geon and the PCP both fail to identify a fracture as a fragility 
fracture, the bone metabolism is not studied and so osteo-
porosis is not diagnosed. Even in cases of evident spinal 
deformity, patients are often not treated until vertebral frac-
tures do not produce symptoms such as chronic pain. Dual 
energy X-ray absorptiometry (DEXA) is the gold standard 
for the diagnosis of osteoporosis, but this exam is not always 
prescribed, even after a fragility fracture or in the presence 
of risk factors. Also, even when a diagnosis of osteoporosis 
has been made, physicians do not always prescribe drugs to 
reduce the risk of future fractures. This situation is responsi-
ble for more than 240,000 hospital admissions in Italy each 
year, which costs the health system €1.5 billion. For this 
reason, osteoporosis should be considered a public health 
priority.
In conclusion, after a fragility fracture, the PCP should 
be involved in a tertiary prevention program (FLS). In fact, 
as they have had the opportunity to follow the patient in 
detail, outside of the hospital, and given their knowledge of 
the patient’s overall clinical course, the PCP has the oppor-
tunity to check that the patient is correctly adhering to the 
prescribed therapy and to monitor for the onset of more 
severe conditions, thus acting as a natural link between the 
patient, the orthopedist, and the bone specialist (grade A 
recommendation).
Figure 8 summarizes the recommendation statements for 
integrated approaches to osteoporotic fractures as a toolbox.
Conclusions
The Italian Society for Orthopaedics and Traumatology 
has produced up-to-date Italian guidelines for the primary, 
secondary, and tertiary prevention of osteoporosis and 
Fig. 8  Toolbox for guidance: integrated approaches
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osteoporotic fractures. This guidance is primarily addressed 
to Italian orthopedic surgeons, but should also prove use-
ful to other bone specialists and general practitioners who 
wish to optimize the diagnosis, prevention, and treatment 
of osteoporosis and its consequences. More effective inter-
actions between the various health professionals involved 
in this field are needed to improve outcomes, as demon-
strated by the successful implementation of FLS throughout 
Europe. Comprehensive assessment of the risk of fracture, 
beyond simply assessing the BMD, is crucial to any program 
aiming at the primary, secondary, and tertiary prevention of 
osteoporosis.
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